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Abstract 
 
Shape-based approaches have many potential areas for development in the future for 
application to in silico pharmacology. Further exploration of the role of molecular 
shape may lead to better understanding of the substrate specificity of enzymes and the 
possibility to reduce toxic effects that may be caused by ligands binding to undesired 
target proteins. Methods exploiting molecular shape for activity and toxicity 
prediction might have a great influence on the drug discovery process.  
There are different approaches that might be used for this purpose, e.g. shape 
fingerprints and shape multipoles. Both methods describe the shape of molecules, 
discarding any chemical information, using numerical values. Focusing only on shape 
can lead to identifying novel core structures of molecules, with improved properties. 
 Molecular fingerprints are binary bit strings that encode the structure or shape of 
compounds; shape is measured indirectly by alignment to a database of standard 
molecular shapes – the reference shapes. The Shape Database should represent a wide 
range of possible molecular shapes to produce accurate results. Therefore, this was the 
main focus of the investigation. 
The shape multipoles method is a fast computational method to describe the shape of 
molecules by using only numbers and therefore it requires low storage needs and 
comparison is performed by simple mathematical operations. To describe the shape, 
it uses only 13 values (3 quadrupole components and 10 octupole components). 
The performances of both methods in grouping compounds based on shared biological 
activity were evaluated using several test sets with slightly better results in case of 
shape fingerprints. However, the shape multipole approach showed potential in 
finding differences in shape between enantiomers. Among the possible applications of 
the shape fingerprints method are solubility prediction (on comparable level as well-
established methods) and virtual screening. 
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List of abbreviations 
 
 
 
AChE Acetylcholinesterase 
AHR Aryl Hydrocarbon Receptor 
AKT1 Serine/Threonine-protein Kinase AKT 
AMPC AmpC Beta-lactamase 
AUC Area Under Curve 
AV method Average Value method 
BOV  
 
Bit On Value, threshold value used in shape fingerprints 
generation process 
Cav 3.2 Voltage-gated calcium channel subunit alpha Cav3.2 
CoMFA Comparative Molecular Field Analysis 
CoMSIA Comparative Molecular Similarity Index Analysis 
CP3A4 Cytochrome P450 3A4 
CXCR4 C-X-C Chemokine Receptor type 4 
D1 Dopamine D1 receptor 
DBD DNA Binding Domain 
DPP-IV Dipeptidyl peptidase IV 
DT Design Tanimoto, threshold value used in Shape Database 
generation process 
EGFR Epidermal Growth Factor Receptor 
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VDR Vitamin D Receptor 
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Chapter 1  
 
 
 
Theoretical Background 
 
 
 
 
 
1.1. Introduction  
By definition, shape is the form of an object or its external boundary, outline, or 
external surface. Shape is used by everyone on a daily basis as a way of identifying 
and organizing visual information. Shapes are also the very first thing children learn 
in early childhood – it is because shape is one of the very noticeable attributes of the 
world around us.1 Before learning the name of the object, we use the description of it 
– its shape and colour, which helps us to visualize things and to help others understand 
what object we are describing.1 Although shapes like triangles, squares or circles that 
are present in the macroworld are not difficult to describe, it is not easy to define more 
complex shapes, especially those that build the microworld – the shape of molecules.  
1.2. Importance of shape in chemistry and biology 
There are many different biological processes in all organisms that distinguish 
molecules based on their shape. The size and spatial features of molecules play a 
crucial role in activation of G-protein-coupled receptors (which are responsible for 
regulation of diverse cell functions), opening ligand-gated ion channels (e.g. 
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participating in neurotransmission), antibody recognition and activation of a variety 
of enzymes (Figure 1-1).2,3,4 
 
Figure 1-1. Lock and key model – antibodies memorize pathogens mostly based on 
their shape. 2 
 
This ability of proteins to bind ligands with specific shapes was first explained by Emil 
Fischer5 in 1894 and later further explored by Linus Pauling6 during his scientific 
work. In the proposed “lock-and-key” model a substrate is treated as a key that needs 
to fit perfectly, by the means of size and shape complementarity, to a conceptual lock, 
which is the binding site of a target protein (Figure 1-2). Many ligand-protein 
complexes were analysed in the past to examine this theory, only to come to the 
conclusion that even though the ligand adapts multiple conformations, which are 
difficult to predict, the lock and key concept is still the working model for designing 
new compounds in many areas of study.3 The theory was broadly studied especially 
for its usage in rational drug design.7,8,9 A lot of computational methods like molecular 
docking and pharmacophore modelling were developed based on the hypothesis that 
a ligand needs to match the active site of the target protein in terms of shape and more 
besides.  
The image originally presented here cannot be made freely available via LJMU 
E-Theses Collection because of copyright restrictions. The image was sourced 
at: 
Zhang, J. X. J.; Hoshino, K. Chapter 1 - Introduction to Molecular Sensors. In 
Molecular Sensors and Nanodevices; Zhang, J. X. J., Hoshino, K., Eds.; 
William Andrew Publishing: Oxford, 2014; pp 1–42. 
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Figure 1-2. Complex of the human HMG-CoA reductase with Atorvastatin as an 
example of the lock and key model (pdb code: 1HWK).10 
Nowadays, there are two main approaches in similarity searching: based on chemical 
or shape similarity. Relying on the chemical structure or shape of known drugs to 
screen databases in order to find the compounds that might have a desired potency has 
a background in bioisosterism.11,12,13,14 The concept was introduced by Friedman15 and 
implies that molecules that are similar in size and shape are more likely to show similar 
activity towards the same target macromolecule.16 More common are simple isosteric 
replacements, which involves the substitution of a group of atoms in one compound 
by others with similar shape or chemistry,14 e.g. changing OH group with NH2. 
Bioisosterism concerns more drastic changes, more important or bigger groups of the 
ligand, like replacement of the core of the molecule (Figure 1-3).11,14 
 
 
 
Figure 1-3. Example of bioisostere replacement: oxygen atom is being replaced by 
triazolone.17 
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The pharmaceutical industry uses this concept to improve potential drugs, which, 
although they show a desired activity, cause side effects. It may also lead to 
improvement of potency and changes in physicochemical properties, such as 
solubility.14 Thus, a principle motive behind many virtual screening studies is to find 
compounds similar in shape and size, meaning that they show similar activity, but 
different enough to have physicochemical properties that may improve drug action 
and reduce toxicity.16,18 It can be also applied to find analogues of a drug that cannot 
be introduced to the market because of intellectual property rights. 
1.3. Structure-based vs. ligand-based methods 
Implementation of Fischer’s theory can be found in many tools used by scientists, 
mostly focusing on receptor-based approaches.7 Such methods, e.g. molecular 
docking,19 can predict the interactions that occur between the potential drug and its 
receptor. Molecular docking, since its introduction in 1982,20 has been proved to be a 
very successful technique.19,21,22 Its usefulness in predicting the ligand poses in the 
binding pocket as well as its ability to estimate the binding energy based on the formed 
non-covalent interactions, made it the leading technique in drug discovery (Figure 
1-4).23,24  
 
Figure 1-4. 2,5-dibromo-N-{(3R,5S)-1[(Z)-iminomethyl]-5-methylpyrrolidyn-3-
yl}benzenesulfonamide docked, using AutoDock, in the active site of cathepsin C (pdb 
code: 3PDF) with shown interactions. 
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However, all receptor-based techniques need sufficient data about the structure of the 
receptor or at least about its binding site.25 This might be challenging, because current 
protein structure databases may not provide the necessary structures or structures of a 
good enough quality and this way it may lead to inaccurate calculations.26 
Additionally, ligand-based approaches are usually much faster than docking methods. 
Those are major reasons that ligand-based methods (which do not require information 
about the receptor’s structure) can be useful in the early stages of the drug discovery 
process, especially in lead generation and lead optimization.27 Screening thousands or 
tens of thousands of compounds in order to discover a new drug, similar to the known 
ligand or lead compound, that would bind to the target better or cause less side effects 
is commonly used in the pharmaceutical industry.28,29,30 
1.4. 2D methods  
When structural data of the receptor is unknown or is of poor quality, the ligand-based 
drug design is preferred.26,31 Ligand-based approaches use the information of one or 
more known ligands of the protein.32,33 The underlying hypothesis is that molecules 
with similar features to the already known actives are more likely to have comparable 
biological activity.34 Among the most common approaches, there are methods based 
on chemical similarity and QSAR (quantitative structure–activity relationship) 
models, 26,31 which predict the activity/properties of molecules based on their chemical 
structure.35,36  
Most ligand-based techniques assign descriptors to the molecular structures to later 
compare and rank the molecules based on the similarity scores. The ligand-based 
methods used in medicinal chemistry relate to 2D structures of molecules, because of 
the simplicity and speed of such approaches. The similar molecules that show 
neighbourhood behaviour have similar representations as SMILES strings29,37 
(Simplified Molecular Input Line Entry Specification)38 or similar fingerprints. 39  
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1.4.1. 2D fingerprints 
There are ligand-based methods that encode the 2D structure of a molecule or its 
features using bit string representations. Such an approach is termed as molecular 2D 
fingerprints and these are one of the most commonly used methods in drug discovery 
nowadays.28,39,40,41,42 Their focus is on chemical similarity searching, therefore that is 
the information encoded in their bit strings. There are several types of molecular 
fingerprints with different fragmentation strategies (e.g. linear, radial, dendritic), atom 
types (e.g. generic, where all atoms and bonds are equivalent, functional, where atoms 
are distinguished by functional type or atoms recognized as hydrogen bond acceptors 
or donors), bit scaling rules (e.g. scaling by feature size to molecule size) and similarity 
indices.41,43  
Among the commonly used 2D fingerprints are MACCS,44 LINGO,45,46 Circular,47 
Path and Tree.40 The summary of them can be found in Table 1-1. Some of the 
fingerprints generation processes do not assign a specific feature to a bit position and 
use the hash function to map the information of molecular structure into a fixed size 
bit string.43 In such fingerprints it is therefore common to observe bit collisions, where 
the bit is set on for more than one fragments/feature.43 These are topological 
fingerprints, which are often called hashed fingerprints.43 
Table 1-1. 2D fingerprint methods and descriptions.  
FINGERPRINT 
METHOD 
DESCRIPTION 
MACCS 166 or 960 bit structural key descriptors based on SMARTS 
patterns 
CIRCULAR enumerated circular fragments hashed into a fixed-length bit 
string 
LINGO text-based molecular similarity search method based on 
fragmentation of canonical isomeric SMILES strings 
TREE enumerated tree fragments hashed into a fixed-length bit string 
PATH enumerated linear fragments hashed into a fixed-length bit 
string 
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1.4.1.1. MACCS   
MACCS keys, also known as MDL 2D keysets, are structural keys based on SMARTS 
patterns.44 This type of fingerprint encodes the presence or absence of a given 
substructure in a molecule, as shown in the Figure 1-5. 
 
Figure 1-5. Example of the hypothetical 10-bit substructure.40  
There are two possible lengths of a MACCS fingerprint – 960 or 166 bit.40,44 The most 
used is the shorter version, which covers most of the interesting chemical features for 
drug discovery and virtual screening and it is available in many software packages.40  
1.4.1.2. Path and Tree fingerprints 
Path-based and Tree fingerprints are both topological fingerprints, in which the 
fragments are analysed either in a tree or a linear way up to a given size (a certain 
number of bonds) and then all those paths are hashed into a fingerprint.40 Unlike in 
MACSS fingerprints, the particular bits cannot be traced back to certain chemical 
features as some of them might encode more than one feature. These fingerprints are 
suitable for substructure queries.40  
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Figure 1-6. Example of a hypothetical 10-bit path-based fingerprint.40  
1.4.1.3. Circular fingerprints 
Circular fingerprints are also topological fingerprints.47 However, as the name 
suggests, the radius of each heavy atom of a molecule is analysed. ECFPs (Extended-
connectivity fingerprints) are circular fingerprints based on the Morgan algorithm.40 
This type of fingerprint cannot be used for substructure queries and are rather used for 
similarity searches of the whole structure.40  
 
Figure 1-7. Example of hypothetical 8-bit circular fingerprint.  
The image originally presented here cannot be made freely available 
via LJMU E-Theses Collection because of copyright restrictions. 
The image was sourced at 
Cereto-Massagué, A.; Ojeda, M. J.; Valls, C.; Mulero, M.; Garcia-
Vallvé, S.; Pujadas, G. Molecular Fingerprint Similarity Search in 
Virtual Screening. Methods 2015, 71, 58–63. 
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1.4.1.4.  LINGO 
LINGO fingerprints are text strings45 instead of bit strings like other fingerprints types. 
Their string includes different letters, numbers and symbols, which are obtained by 
decomposing a SMILES string.45,46 As described by Vidal et al.:45 “a q-LINGO is a 
q-character string, including letters, numbers and symbols, such as “(“, “)”,“[“, “]”, 
“#”, etc. obtained by stepwise fragmentation of a canonical SMILES molecular 
representation”. The SMILES string of length n would result in (n-(q-1)) substrings 
of length q. As shown in the Figure 1-8, where q=4, the chlorpromazine is 
decomposed into 25 substrings, with three of them having two occurrences, which is 
28 in total (31-(4-1) = 28).  
 
Figure 1-8. LINGO generation process.45 
1.4.2. Similarity measures   
When comparing two molecular fingerprints, the presence or absence of a structural 
fragment is represented by setting a bit On or Off. Therefore, similar molecules are 
the ones with a higher number of bits in common, which indicates possession of 
similar features or functional groups. 
The comparison is performed by alignment of two molecules – the query and the one 
from the database, or more accurately their bit strings, and counting the number of bits 
set on in only one of the strings and those in common. The results are scored using 
one of many similarity coefficients. The most common metrics are the Tanimoto, 
The image originally presented here cannot be made freely available via 
LJMU E-Theses Collection because of copyright restrictions. The image 
was sourced at 
Vidal, D.; Thormann, M.; Pons, M. LINGO, an Efficient Holographic Text 
Based Method To Calculate Biophysical Properties and Intermolecular 
Similarities. J. Chem. Inf. Model. 2005, 45 (2), 386–393. 
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Tversky, Cosine, Euclidean and Dice.40,48 The summary of the popular similarity 
measures can be seen below in Table 1-2.  
Table 1-2. Most popular similarity measures. 
TYPE FORMULA RANGE 
TANIMOTO 𝑏𝑜𝑡ℎ𝐴𝐵
𝑜𝑛𝑙𝑦𝐴 + 𝑜𝑛𝑙𝑦𝐵 + 𝑏𝑜𝑡ℎ𝐴𝐵
 [0.0 – 1.0] 
TVERSKY 𝑏𝑜𝑡ℎ𝐴𝐵
𝛼 ∗ 𝑜𝑛𝑙𝑦𝐴 + 𝛽 ∗ 𝑜𝑛𝑙𝑦𝐵 + 𝑏𝑜𝑡ℎ𝐴𝐵
 [0.0 –  N]  
COSINE 𝑏𝑜𝑡ℎ𝐴𝐵
ඥ(𝑜𝑛𝑙𝑦𝐴 + 𝑏𝑜𝑡ℎ𝐴𝐵) ∗ (𝑜𝑛𝑙𝑦𝐵 + 𝑏𝑜𝑡ℎ𝐴𝐵)
 [0.0 – 1.0] 
EUCLIDEAN 
ඨ
𝑏𝑜𝑡ℎ𝐴𝐵 + 𝑛𝑒𝑖𝑡ℎ𝑒𝑟𝐴𝐵
𝑜𝑛𝑙𝑦𝐴 + 𝑜𝑛𝑙𝑦𝐵 + 𝑏𝑜𝑡ℎ𝐴𝐵 + 𝑛𝑒𝑖𝑡ℎ𝑒𝑟𝐴𝐵
 
[0.0 – 1.0] 
DICE 2 ∗ 𝑏𝑜𝑡ℎ𝐴𝐵
𝑜𝑛𝑙𝑦𝐴 + 𝑜𝑛𝑙𝑦𝐵 + 2 ∗ 𝑏𝑜𝑡ℎ𝐴𝐵
 [0.0 – 1.0] 
 
In the table above (Table 1-2), bothAB represents the number of common features for 
the molecules A and B, neitherAB is the number of bits set off in common for 
molecules A and B, while onlyA and onlyB are the numbers of the features present 
only in the molecule A and B, respectively.  
1.4.3. Matched Molecular Pairs 
Another, widely used ligand-based 2D approach is Matched Molecular Pair Analysis 
(MMPA). The key principle of MMPA is that the difference in properties is more 
easily and accurately predicted than the absolute value of properties.49,50 The concept 
was first introduced by Kenny and Sadowski in 2005.51 The method is used to screen 
large databases in order to find pairs of molecules with a common structural part with 
a promising change in properties.49,51,52 A Matched Molecular Pair (MMP) involves 
two compounds that have a common core and have a different fragment R as shown 
in Figure 1-9.  
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Figure 1-9. An example of pair of MMP with fragment part marked in red circle. 
There are two common approaches to finding MMPs: Fragment and Index (F+I)53 and 
Maximum Common Substructure (MCSS).54 In the MCSS approach, as used in the 
WizePairZ algorithm described by Warner et al.,54 two molecules are compared and 
the maximum common substructure shared by them is identified – the fixed part. The 
remaining part is called the changing part. In order to compare the molecules using 
this approach, the molecules are converted into graphs, which enables identifying 
common substructures between compounds.  
The outcome of the MCSS approach is governed by the choices made about deciding 
what to classify as a pair. Warner et al.54 elected to use a fast graph comparison 
technique that does not permit disconnected substructures to be generated and chose 
to limit the changing part of the molecule to be less than 10% of the fixed part.49 They 
encoded the output from their pair finding as SMIRKS (reaction transform language)55 
that permits any structural changes identified as being of interest to be able to be 
applied to molecules to which they may be relevant.54 
The key limitations of the MCSS approach are that the substructure comparison is 
slow and that most algorithms for finding the MCSS require all of the atoms to be 
contiguous and therefore prevent pairs in which linkers change from being found.49 
The second approach was introduced by Hussain and Rea.53 The algorithm works by 
generating fragments of the molecule based on predefined rules and then indexing 
those fragments. The generated fragments are stored as key – value pairs.53,56  
OH
N
N
N
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Figure 1-10. Scheme of identifying pairs in the Fragment and Index approach when 
single cuts are performed. 
In the first step, each molecule is fragmented, by breaking selected bonds (Figure 
1-10). Hussain and Rea53 achieve this by defining the bonds to be broken using a 
SMARTS pattern. They aim to have this pattern be specific to acyclic single bonds. 
Bonds are broken one at a time, and the resulting fragments are then stored as SMILES 
strings, which can be manipulated as text.49,53 This is a great advantage of the 
approach: after initial fragmentation, all subsequent steps toward the identification of 
matched pairs involve only rapid text processing.49 Also, once a molecule has been 
fragmented and added to the database, it is available to any new molecule that is added.  
Among the limitations of the fragment and index approach to finding matched pairs 
are that small changes to rings cannot be identified as pairs, highly substituted core 
changes are limited by the number of fragmentations considered, and the diversity of 
the structural changes can be limited by the restrictions that are imposed (usually 
heavy atom counts or ratio).49 One specific set of changes that are not readily identified 
is modifications to macrocyclic rings.  
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Table 1-3. Advantages and disadvantages of MCSS and F+I approaches.  
METHOD ADVANTAGES DISADVANTAGES 
MCSS  small changes to rings 
can be identified 
 
 slow  
 most algorithms for finding 
the MCSS require all of the 
atoms to be contiguous 
F+I  fast 
 once a molecule has 
been fragmented and 
added to the database, it 
is available to any new 
molecule that is added 
 restrictions in bond 
breaking - small changes to 
rings cannot be identified 
 can lead to fragmentations 
and grouping into sets of 
pairs that chemists would 
not normally consider to be 
chemically sensible 
 
 
1.5. Scaffold hopping – chemistry vs. shape 
There are many approaches that rely on the chemistry of the molecule, discarding the 
information about the three-dimensional shape of a molecule. Those approaches rarely 
lead to compounds that are chemically very distinct and thus they are not well-suited 
for scaffold hopping.57,58 Knowing that molecules similar in shape could bind to the 
same protein even with completely different chemistry, opens new possibilities to find 
novel, sometimes unexpected compounds.  
 
 
 
 
Figure 1-11. Example of scaffold hopping. 
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Therefore, scaffold hopping gains a lot of attention in medicinal chemistry. The 
concept was introduced in 1999 by Schneider et al.59 It is a technique that identifies 
compounds with different chemistry or central core but with similar shape or 
electrostatic surface and thus leading to comparable or improved activity.57,58,60,61 The 
scaffold hopping can lead to drastic changes in molecular properties, e.g. changes in 
solubility by replacing a lipophilic structure with a more polar one, changes in the 
stability of a compound, reduction of toxicity, or improvements in DMPK (drug 
metabolism and pharmacokinetics).57  
There are many successful compounds identified using scaffold hopping. One of the 
examples can be seen in the Figure 1-12. The structure of morphine and tramadol is 
very different but they share positions of the tertiary amine, the aromatic ring, the 
hydroxyl group and also have some similarities in the overall shape.61,62 
 
A) 
 
B) 
 
Figure 1-12. Structures of pain killing drugs: Morphine (A) and Tramadol (B). 
Molecules with different core structures but similar activity are of high interest in 
medicinal chemistry mostly due to a desire to improve potency or reduce toxicity.16 It 
can be also applied to find analogues that are novel and patentable.  
1.6. 3D methods  
More and more methods are used for describing molecular shape. Among them, the 
most common and simple are pharmacophores.63 Pharmacophores are defined as 
arrangement of atoms or the features of molecule that are essential in its biological 
activity.58,63 It uses the information of hydrogen donors or acceptors, acidic/basic 
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groups and hydrophobic features in the molecule and their position in space.63 
However, that approach may not accurately indicate the shape because of treating the 
shape of molecule just as sets of atoms in space and not focusing on its volume and 
surface (Figure 1-13).  
 
Figure 1-13. The example of a pharmacophore model with three pharmacophoric 
features: one hydrogen bond acceptor (green), one hydrophobic feature (blue), and an 
aromatic ring (orange).64 
CoMFA (Comparative Molecular Field Analysis)65 is a 3D-QSAR method that links 
the shape-dependant properties of molecules to their biological activity.32 The 
molecules binding to the same receptor and in the same way are selected to develop 
the models.32,66,67 Then they are aligned based on their shape and their molecular fields 
are mapped to the 3D grid.32,67 Field values in each grid point are calculated 
corresponding to the potential energy, which is then correlated to biological 
activity.32,67 Similarly, CoMSIA (Comparative Molecular Similarity Indices)66,68 is 
also a 3D-QSAR model, but includes the hydrophobic, hydrogen-bond donor and 
acceptor together with steric features.66 
The other methods often used are shape fingerprints,69 Gaussian-based methods70 and 
moment-based method (e.g. the shape multipole method).71 These methods do not 
require chemical information and depend only on the spatial distribution of shape. 
Therefore, they might be more appropriate for scaffold hopping approaches. 
The image originally presented here cannot be made freely 
available via LJMU E-Theses Collection because of 
copyright restrictions. The image was sourced at 
Fei, J.; Zhou, L.; Liu, T.; Tang, X.-Y. Pharmacophore 
Modeling, Virtual Screening, and Molecular Docking Studies 
for Discovery of Novel Akt2 Inhibitors. Int. J. Med. Sci. 
2013, 10 (3), 265–275. 
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1.6.1. Gaussian-based methods – ROCS 
A Gaussian description of molecular shape is implemented in ROCS,72 which stands 
for Rapid Overlay of Chemical Structures, is an Openeye’s software. Two or more 
molecules are compared according to their volume overlap. The method, which 
describes molecules in terms of atom-centred Gaussian functions, performs 
optimization by rigid translation and rotation of one of the matched molecules with 
respect to the other.70 The difference between two shapes is returned as a Tanimoto or 
Tversky coefficient ranked from the highest to the lowest values.  
The ROCS package72 allows for addition of chemical feature information that can be 
used together with volume overlap to compare molecules. For these, various scores 
might be used e.g. TanimotoCombo, TverskyCombo, which includes the chemical 
information as well as shape and compares the compounds in different ways. 
Additionally, multi-conformer molecules can be used as both query and database 
molecules. However, applying these features requires more computational time. 
1.6.2. Shape fingerprints 
Fingerprint methods are not only used to describe the chemical connectivity of a 
molecule, e.g. LINGO or Tree fingerprints, but may also be applied to encode the 
shape of the molecule – via so called shape fingerprints.69 Haigh et al.69 introduced the 
concept of shape fingerprints and established the parameters that can be varied to tune 
the fingerprint. The shape of a molecule is measured indirectly by alignment to a 
database of diverse reference shapes, as shown in the example in Figure 1-14. 
Therefore, to produce accurate results, the database with reference shapes is supposed 
to represent a wide range of possible shapes of molecules to produce accurate results.  
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Figure 1-14. The example of shape fingerprint generation process for aspirin with a 
hypothetical set of reference shapes and BOV of 0.5. 
The corresponding bits are turned on or off depending on whether the similarity 
between the shape of molecules (defined by Shape Tanimoto (ST), which is calculated 
as shown in Equation 1-1) is greater or smaller than the cut-off value. 
Equation 1-1. Shape Tanimoto. 
𝑆𝑇஺஻ =  
𝑉஺஻
𝑉஺஺ +  𝑉஻஻ − 𝑉஺஻
 
 
Where VAB is the Gaussian overlap volume of the two molecules (A and B) aligned in 
such a way as to maximize the overlap. VAA and VBB are self-overlap volumes. Shape 
Tanimoto can vary from 0 (for the most dissimilar shaped molecules) to 1 (for 
molecules of identical shape). 
The shape similarity measurement is obtained by comparisons of bit strings in the 
created fingerprints, in the exact same way as described in section 1.4.2 about the most 
common similarity coefficients used in molecular fingerprint methods. 
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1.6.3. Moment-based methods – shape multipoles 
There are many methods characterizing shape by a set of descriptors, which allow for 
much faster screening of even large libraries of conformations. One such method is 
the shape multipole method, developed by A. Grant and B. Pickup.71 They described 
the algorithm for calculation of shape multipoles based on Gaussian density, which 
allows fast comparison of molecular shapes.  
Sets of descriptors need to be generated for the comparison phase - centroids and 
multipoles (monopole, dipoles, quadrupole, octupole moments). These are used to 
generate a quantitative comparison of the molecules by the sums of differences. It is 
assumed that a more detailed estimation of shape is obtained when higher order 
multipoles are calculated and used for comparison. 
Reduction of the time needed for comparison of two molecules is achieved by purely 
describing shape as numbers - thus those approaches are often labelled as numerical 
methods. The centroids and multipoles required for a similarity search can be 
computed at negligible cost.  
 
Figure 1-15. The visualisation of l=2 to l=8 multipole moments.73 
In physics the electric dipole moment (Figure 1-15) is used to describe the distribution 
of charge within a system, as shown in Equation 1-2 and the analogous equation can 
be written based on Gaussian density (Equation 1-3).71 
The image originally presented here cannot be made freely available via 
LJMU E-Theses Collection because of copyright restrictions. The image 
was sourced at 
Copi, C. J.; Huterer, D.; Starkman, G. D. Multipole Vectors--a New 
Representation of the CMB Sky and Evidence for Statistical Anisotropy or 
Non-Gaussianity at 2<=l<=8. Phys. Rev. D 2004, 70 (4). 
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Equation 1-2. Electric dipole moment, defined as the first order of the electric 
multipole expansion, where ρelec is electrostatic charge density and r is a Cartesian 
coordinate of a point. 
𝑝 = න 𝑟𝜌௘௟௘௖ (𝑟)𝑑𝑟 
Equation 1-3. The first order term in the shape multipole expansion, where V is 
defined as the Gaussian volume, rα, rβ, rγ, etc. are the Cartesian coordinates of a point 
and ρg is Gaussian density of a molecule. 
𝑆ఈ
(ଵ) =
1
𝑉
 න 𝑟ఈ𝜌௹
௚ (𝑟)𝑑𝑟 
Higher order terms, shape quadrupoles and octupoles, can be defined as in Equation 
1-4 and Equation 1-5, respectively, leading to a more and more accurate description 
of the shape of a molecule.  
Equation 1-4. Shape Quadrupole, the second order moment. 
𝑆ఈఉ
(ଶ) =
1
𝑉
 න 𝑟ఈ𝑟ఉ𝜌௹
௚ (𝑟)𝑑𝑟 
Equation 1-5. Shape Octupole, the third order moment.  
𝑆ఈఉఊ
(ଷ) =
1
𝑉
 න 𝑟ఈ𝑟ఉ𝑟ఊ𝜌௹
௚ (𝑟)𝑑𝑟
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Chapter 2  
 
 
 
Shape Fingerprints 
 
 
 
 
 
2.1. Introduction 
One commonly used ligand-based approach is molecular fingerprinting in which 
binary bit strings encode the structure of compounds allowing fast calculations with 
low storage needs.40 There are many types of fingerprints and most encode only the 
atom types and how they are connected to one another and so do not describe the three-
dimensional character of molecules.41,74,39,47,45,40,75 However, these techniques rarely 
lead to compounds that are chemically very distinct and thus they are not well-suited 
for scaffold hopping wherein compounds are sought that have a desired activity, but 
are different enough to have improved ADMET properties (and hopefully are novel 
and patentable). 57,76 
By contrast, the shape fingerprint method encodes only the shape of compounds and 
not chemical structural information.77 The shape of a molecule is measured indirectly 
by alignment to a database of diverse reference shapes. To be effective, these reference 
shapes must represent all shapes of molecules that are likely to bind to proteins. With 
a set of reference shapes in hand, shape similarity can be assessed by comparisons of 
the bit strings in the created fingerprints. Previous work of Haigh et al.77 has outlined 
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the concept of shape fingerprints and established the parameters that can be varied to 
tune the fingerprint. However, a link between shape fingerprints and biological activity 
has never been established. This chapter shows how the description of shape via 
fingerprints for the explanation of biological activity was optimized. It presents the 
results of such optimization and shows that shape fingerprints are able to group 
molecules that are similar enough to have shared biological activity. Further, it 
describes the optimal method for making this link and makes the data needed to 
perform these calculations available. 
2.2. Methods 
2.2.1. Creating a database of reference shapes 
In the work described in this chapter, sets of reference shapes were generated by 
implementation of the algorithm previously described by Haigh et al.77 The algorithm 
(which uses Openeye’s Shape Toolkit 78) randomly selects a first reference molecule 
out of the input dataset. The remaining molecules in the dataset are compared to the 
reference molecule and a Shape Tanimoto (ST) calculated that can be defined as: 
𝑆𝑇஺஻ =  
𝑉஺஻
𝑉஺஺ +  𝑉஻஻ − 𝑉஺஻
 
 
Where VAB is the Gaussian overlap volume of the two molecules (A and B) aligned in 
such a way as to maximize the overlap. VAA and VBB are self-overlap volumes. Shape 
Tanimoto can vary from 0 (for the most dissimilar shaped molecules) to 1 (for 
molecules of identical shape). Molecules with ST greater than a user-selected value 
(the Design Tanimoto, DT) were discarded. The molecule with the smallest ST was 
then selected as the next reference molecule and the same process repeated until all 
molecules have either been selected as a reference shape or discarded (Figure 2-1).  
Thus, Design Tanimoto defines how similar are the shapes that are forming the Shape 
Database. Each set of reference shapes forms a Shape Database, referred to here as 
SDx where x is a distinguishing number. 
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Figure 2-1. The workflow of Shape Database generation process. 
2.2.2. Generating shape fingerprints 
Shape fingerprints were generated by comparing a query molecule with each reference 
shape in the Shape Database in turn. As shown in the Figure 2-2, for each reference 
shape, if the ST was above another user-defined value, the Bit-On Value (BOV) then 
the corresponding bit was set to 1 and if below the BOV, the bit was set to 0, and this 
way producing the bit string of length equal to number of shapes included in Shape 
Database.  
Select Dataset
Select Seed 
Molecule
Calculate Shape 
Tanimoto
Reject Molecules 
with ST higher 
than DT 
Retain molecules with 
ST lower than DT 
(New Database)
Select Molecule with the 
lowest ST (New Seed 
Molecule)
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Figure 2-2. The example of the shape fingerprint generation process for aspirin with 
a hypothetical set of reference shapes and BOV of 0.5. 
All the molecules were compared by aligning their bit strings, counting the number of 
bits set on (at 1) only in one of the strings and those set on in both strings. Bit Strings 
for molecular shapes A and B were compared using the Fingerprint Tanimoto (FT) as 
a similarity measure: 
𝐹𝑇஺஻ =  
𝑏𝑜𝑡ℎ𝐴𝐵
𝑜𝑛𝑙𝑦𝐴 + 𝑜𝑛𝑙𝑦𝐵 + 𝑏𝑜𝑡ℎ𝐴𝐵
 
 
Where onlyA and onlyB are the numbers of unique bits on in the bit strings for A and 
B respectively, while bothAB is the number of bits on in common to A and B. 
Fingerprint Tanimoto similarity values vary from 0 (for dissimilar compounds) to 1 
(for the most similar molecules).  
2.3. Analysis 
The evaluation of the shape fingerprints approach was performed by employing two 
test sets: 1) a set described by Taylor et al.,79 which was devised to test pharmacophore 
models and consists of 87 molecules binding to 10 different proteins as shown in 
Table 2-1 2) a group from the Astex diversity set,80 which includes 45 molecules 
binding to 4 selected proteins, shown in Table 2-2. 
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Table 2-1. Test Set 1 -  Test set described by R. Taylor et al. 79 used for validation of 
the shape fingerprints method. 
PROTEIN NUMBER OF 
COMPLEXES 
PDB CODES 
Protein kinase 5 (PK5) 2 1v0o, 1v0p 
Fatty acid binding 
protein (FABP) 
3 1tou, 1tow, 2hnx 
Neprilysin (NEP) 4 1dmt, 1r1h, 1r1j, 1y8j 
Dihydrofolate reductase 
(DHFR) 
6 1drf, 1hfr, 1mvt, 1pd9, 1s3v, 2dhf 
Checkpoint kinase 
(Chk1) 
16 1nvq, 1nvr, 1nvs, 1zlt, 1zys, 2br1, 
2brb, 2brg, 2brh, 2brm, 2bro, 2c3l, 
2cgu, 2cgw, 2cgx, 2hog 
Neuraminidase (NEU) 11 1a4g, 1a4q, 1b9s, 1b9t, 1b9v, 1inf, 
1inv, 1ivb, 1nsc, 1nsd, 1vcj 
Carbonic anhydrase 
(CA) 
13 1bn3, 1bn4, 1bnq, 1cim, 1eou, 1if7, 
1oq5, 1xpz, 1zgf, 1zh9, 2eu3, 2hoc, 
2nng 
Adenosine deaminase 
(ADA) 
11 1krm, 1ndv, 1ndw, 1ndy, 1o5r, 1qxl, 
1uml, 1v7a, 1v79, 1wxy, 2e1w 
Heat shock protein 90 
(HSP) 
10 1byq, 1uy8, 1yc1, 1yc4, 1yet, 2bsm, 
2byi, 2bz5, 2cct, 2uwd 
Acetylcholinesterase 
(AChE) 
11 1dx6, 1e66, 1eve, 1gpk, 1gpn, 1h23, 
1w4l, 1zgb, 2ack, 2c5g, 2ckm 
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Table 2-2. Test Set 2 - Test set made from the selected targets from Astex diversity 
set 80 used for validation of the shape fingerprints method. 
PROTEIN NUMBER OF 
COMPLEXES 
PDB CODES 
Chitinase B 8 1w1p, 1w1t, 1w1v, 1w1y, 3wd1, 3wd2, 
3wd3, 3wd4 
TMK 8 1mrs, 1w2g, 1w2h, 4unn, 4unp, 4unq, 
4unr, 4uns 
Tryptophan Syntase 13 1k3u, 1k7e, 1k7f, 1qop, 1yjp, 1wbj, 
2cle, 2clh, 2clk, 2j9y, 4hpx, 4ht3, 4kkx 
VDR 16 1db1, 1ie8, 1ie9, 1s0z, 1s19, 1txi, 
2ham, 3auq, 3aur, 3ax8, 3kpz, 3vhw, 
3x31, 3x36, 4ite, 5gt4 
 
In order to analyse the results, the ROC curve was used, which is a tool for diagnostic 
test evaluation.81 The ROC curves and AUC values were produced in R.82 Half of the 
matrix without the diagonal was used in these calculations. 
2.4. Conformations 
SMILES were generated using Openeye’s OEChem Toolkit 78 for all the molecules 
shown in Table 2-1 and Table 2-2. Some of the generated SMILES needed manual 
assignment of stereochemistry. Conformations were generated using OMEGA 
software83 with the maximum number of generated conformers set to 5. Shape 
fingerprints were generated for each conformation. When two molecules were 
compared, all fingerprints of one molecule were compared with all those of the other. 
Two summary values for this comparison were investigated: 1) the highest value of 
FT amongst the array arising from comparisons of all conformations of one molecule 
with all conformations of the other is selected – the MV (maximum value) method or 
2) the average of those values is selected – the AV (average value) method.  
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2.5. Results and Discussion 
2.5.1. Defining a set of reference shapes 
A shape fingerprint is a binary encoding of the similarity of the shape of any given 
query molecule to a series of reference shapes. Having an appropriate set of these 
reference shapes is therefore critical. Haigh et al.77 used a set of reference shapes 
generated from the Cambridge structural database of small molecule crystal 
structures84 and a set of conformations generated by CORINA for the MDDR 
database85 of molecules that have been studied clinically.  As there is great interest in 
protein-ligand interactions, thus instead it was chosen to use the database of ligands 
studied by X-ray crystallography in complex with a protein – the Ligand Expo 
dataset.86 At the time, this contained the experimental coordinates for 1,158,763 non-
polymer molecules and non-standard amino acids and nucleotides. Various filtering 
criteria based on molecular weight were applied to these molecules (Figure 2-3), 
leading to 9 databases of shapes that were considered as input to the algorithm that 
was used to generate the sets of reference shapes. An alternative filtering based on the 
number of heavy atoms was also performed and yielded similar effects.  
 
Figure 2-3. The Ligand Expo Dataset 86 was filtered in 9 different ways according to 
the lower and upper limit of molecular weight shown. The number of structures to 
pass the filter criteria is shown. 
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An implementation of the algorithm described by Haigh et al.77 permitted each set of 
ligand structures to be clustered in such a way that every shape had a Shape Tanimoto 
to at least one reference shape that is above a user-selected cut-off called the Design 
Tanimoto (DT). Shape comparisons were performed with Openeye’s Shape Toolkit, 78 
as implemented in ROCS software.72 A randomly selected shape is the first reference 
shape and its Shape Tanimoto (ST) with every other shape in the input database is 
computed. All those that have Shape Tanimoto values above DT are rejected from 
further consideration. After all comparisons have been made, the shape that has the 
lowest Shape Tanimoto with the starting shape is selected and becomes the next 
reference shape in the database. The process is repeated until all shapes have either 
been rejected or selected as a reference shape. During initial investigations, a low (0.5) 
and a high value of DT (0.7) were investigated; lower values of DT lead to smaller 
Shape Databases. 
2.5.2. Evaluating shape fingerprints 
The shape fingerprints were evaluated by computing their ability to correctly group 
the molecules in two test sets. The first test set comprises a set of 87 molecules each 
of which is known to bind to one of ten proteins listed in Table 2-1.79 A second test 
set, shown in Table 2-2,was extracted from the Astex diversity set and comprised 45 
molecules binding to four different proteins.80 Both test sets include only molecules 
with known protein-ligand structures and hence ligand bioactive conformations.  
As described above, the choice of DT influences the size and nature of the Shape 
Database and this was investigated. Shape fingerprints are generated by computing the 
ST between a query structure and every shape in the Shape Database. When the 
calculated ST is above a user-defined cut-off, the Bit On value (BOV), the bit is set 
On (1) otherwise it is set to Off (0). Lower BOVs lead to higher bit densities. In the 
initial testing of the shape databases, a high and low value (0.7 and 0.5 respectively) 
for each of DT and BOV were used. 
The shape fingerprints for every molecule in both test sets were compared to those for 
every other molecule in the set. The comparison yielded another Tanimoto, the 
Fingerprint Tanimoto (FT). Receiver Operating Characteristic curves (ROC curve) 
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were created that plot the true positive rate against the false positive rate.  The 
computed AUC (Area Under Curve) for these is a measure of accuracy, where 0.9 – 1 
represents a perfect test while 0.5 represents a poor one (equivalent to random). The 
AUCs for Test Set 1 are shown in Figure 2-4.  
When DT=0.5 and BOV=0.7, the AUC is rarely distant from 0.5 suggesting no 
discrimination was achieved. The combination of low DT and high BOV leads to a 
low number of bits set On and so these are unlikely to be able to connect molecules 
(which requires bits to be set in common). The best AUC values for this test set was 
obtained for SD05 with DT=0.5, BOV=0.5 (AUC=0.67). The difference between 
AUC values for all settings was small (excluding the aforementioned settings: 
DT=0.5, BOV =0.7) for all databases except for SD05 and SD09. 
 
Figure 2-4. The AUC values for Test Set 1 when applying different settings: DT=0.5 
with BOV=0.5 and 0.7, and DT=0.7 with BOV=0.5 and 0.7. 
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The plot looks quite similar for Test Set 2, as shown in Figure 2-5. Once again, SD09 
performs noticeably worse than the other sets of reference shapes and the combination 
of DT=0.7 with BOV=0.5 provides poor discrimination. The highest AUC values, 
exceeding 0.83, are obtained for SD01 and SD04 with DT=0.5, BOV=0.5 and for 
SD03 and SD06 with DT=0.7 and BOV=0.7. When results for DT=0.5 and BOV=0.7 
are excluded, SD03 performs the best with an average AUC of 0.81, followed by SD01 
and SD02 with the same average AUC of 0.80.  
 
Figure 2-5. The AUC values for Test set 2 with varying settings.  
When the average AUC values obtained from both test sets are computed (excluding 
DT=0.5, BOV=0.7), SD03 and SD06 (with AUCs of 0.71 and 0.70 respectively) stand 
out as best when SD01, the unfiltered shape database, is excluded. The filtering criteria 
used to generate SD03 and SD06 were therefore combined to generate Shape Database 
10 with molecular weight in the range 300 to 500 with the expectation that this would 
provide the best balance of accuracy and speed (76125 molecules pass the filters for 
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consideration in the database generation process, compared to 244031 in SD01, 92465 
in SD03 and 227691 in SD06). 
A) 
 
Average 
0.62 
0.62 
0.63 
0.60 
0.55 
 
B) 
 
Average 
0.81 
0.78 
0.78 
0.74 
0.66 
 
Figure 2-6. The heatmaps generated based on AUC values for Test Set 1 (A) and Test 
Set 2 (B) when using SD01 with varying DT and BOV. 
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0.81 
0.80 
0.76 
0.68 
 
Figure 2-7.  The heatmaps generated based on AUC values for Test Set 1 (A) and Test 
Set 2 (B) set when using SD10 with varying DT and BOV. 
The values of DT and BOV were then systematically varied in steps of 0.05 between 
0.5 and 0.7. As can be seen in Figure 2-6 and Figure 2-7, the AUC values vary less 
for Test Set 1 (Figure 2-6A, Figure 2-7A), than for Test Set 2 (Figure 2-6B, Figure 
2-7B). This might be caused by differences in molecular weight distribution in both 
sets. 79,80  Experience with other datasets had shown that small molecules (about 200 
Da and below) and large molecules (about 800 Da and above) set very few (or no) bits 
and so cannot be correctly described by these shape fingerprints. The molecular weight 
ranges for the two test sets used in the present study are shown in Figure 2-8. In Test 
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Set 2, the range is slightly wider than for Test Set 1 and this may facilitate the correct 
grouping of Test Set 2. The generally good performance suggests that the shape 
databases obtained are applicable to molecules spanning the molecular weight range 
~200 to ~600 and should therefore be useful for most drug-like molecules.  
A) B) 
  
Figure 2-8. The molecular weight distribution of Test Set 1 (A) and Test Set 2 (B).  
When the variation caused by changing DT and BOV is considered in more detail, the 
influence of these settings on the AUC obtained is as shown in Figure 2-6 when using 
SD01 and Figure 2-7 when using SD10. This shows that using BOV=0.55 gives the 
best results on average and thus the impact of DT was considered while BOV was 
fixed. The choice of the best DT requires a consideration of the size of the Shape 
Database, which determines the computational time required to generate each 
fingerprint. When the average AUC value is viewed as a function of the size of Shape 
Database (Figure 2-9), the difference in average AUC value for the two highest values 
of DT for both test sets is quite small (∆AUC is 0.022 and 0.003 for Test Set 1 and 
Test Set 2 respectively), yet the difference in size of the Shape Databases is significant 
(1346 reference shapes). Therefore, SD10 with DT = 0.65 is selected as the best 
performing Shape Database. The results show that for this setting of DT, the optimum 
BOV is 0.6. The recommended settings are therefore to use DB10 with DT=0.65 and 
BOV=0.6 when grouping molecules according to their likelihood of binding to the 
same protein. 
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Figure 2-9. The graphs showing average AUC value as a function of size of Shape 
Database for both test sets when Shape Database 10 was used. 
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B) 
 
Figure 2-10. Logistic regression plot for Test Set 1 (A) and Test Set 2 (B) when using 
SD10 with DT=0.65 and BOV=0.60. The plots were created using R.82 
A) 
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B) 
 
 
Figure 2-11. ROC curve for Test Set 1 (A) and Test Set 2 (B) when using SD10 with 
DT=0.65 and BOV=0.60. The plots were created using R. 82 
Having selected the optimum method, it is useful to define a cut-off value of FT above 
which molecules have a defined likelihood of sharing biological activity. Logistic 
regression permits a continuous variable, such as FT, to be linked with likelihood of 
belonging to a particular class and has been performed for the two test sets. This is 
shown in Figure 2-10 with the frequency histograms of molecules sharing activity 
shown at the top and those that do not share activity at the bottom. This reveals that 
there is some variability between the two test sets such that when FT is above about 
0.6 for Test Set 1 or above about 0.25 for Test Set 2 there is a greater than 50% chance 
of shared biological activity. In situations where trial data on a set of compounds is 
available, it should be used to calibrate the value of FT that should be used as a cut-
off for the purposes of clustering. However, by merging the two datasets (giving an 
evaluation based on 14 protein targets) and performing logistic regression on the 
combined test set (Figure 2-12), we suggest that a value of FT above 0.45 is a 
reasonable estimate of when compounds are more likely to share biological activity 
than not. 
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Figure 2-12. Logistic regression plot Test Set 1 and Test Set 2 combined together 
when using SD10 with DT=0.65 and BOV=0.60. 
2.5.3. Resampling SD10 
Given that the selection of reference shapes begins with a random choice, it is possible 
that the results are dependent upon this starting point. Therefore, SD10 was 
regenerated with DT=0.65 ten more times. Each of the new Shape Databases was used 
to generate fingerprints for both test sets and the AUC value was recomputed. The 
results show little variation (standard deviations vary from 0.002 to 0.033 depending 
on BOV) and can be seen in the Table 2-3 and Table 2-4. On average, with DT=0.65 
the best performance is found when using BOV=0.60. The AUC values of 0.64 and 
0.84 for Test Set 1 and Test Set 2 respectively, are obtained.  
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Table 2-3. The AUC values for 10x resampled Shape Database 10 with DT=0.65 for 
Test Set 1. 
  ITERATION 
  1 2 3 4 5 6 7 8 9 10 
BOV 0.50 0.61 0.61 0.61 0.61 0.61 0.60 0.61 0.61 0.61 0.61 
0.55 0.63 0.63 0.63 0.62 0.63 0.63 0.63 0.63 0.62 0.63 
0.60 0.65 0.65 0.64 0.63 0.63 0.64 0.64 0.64 0.64 0.64 
0.65 0.65 0.64 0.64 0.63 0.63 0.62 0.66 0.62 0.66 0.62 
0.70 0.60 0.55 0.55 0.56 0.59 0.59 0.57 0.60 0.57 0.56 
 
Table 2-4. The AUC values for 10x resampled Shape Database 10 with DT=0.65 for 
Test Set 2. 
  ITERATION 
  1 2 3 4 5 6 7 8 9 10 
BOV 0.50 0.78 0.77 0.77 0.77 0.77 0.78 0.77 0.77 0.77 0.78 
0.55 0.81 0.81 0.81 0.80 0.83 0.81 0.82 0.81 0.80 0.81 
0.60 0.86 0.85 0.85 0.83 0.83 0.86 0.84 0.83 0.82 0.85 
0.65 0.85 0.84 0.81 0.84 0.82 0.84 0.83 0.85 0.82 0.83 
0.70 0.76 0.67 0.76 0.74 0.75 0.74 0.73 0.74 0.68 0.76 
 
 
 
47 | P a g e  
 
2.5.4. Conformations  
Naturally for most shape comparisons that might be of interest, a protein-ligand crystal 
structure would not be a useful requirement and would suggest that the activity of the 
molecule is already known. Therefore, conformations were generated from the 
SMILES string for each molecule in the test sets using Openeye’s OMEGA software,83 
a knowledge-based conformer generator. In this case, relatively limited sets of up to 
five conformations were generated although some molecules in the set were 
conformationally restricted and generated less than this.  
For all the conformations, shape fingerprints were generated using Shape Database 10. 
Two approaches for evaluating the comparison of two molecules were investigated: 
1) the highest value of FT amongst the array arising from comparisons of all 
conformations of one molecule with all conformations of the other (MV) or 2) the 
average of those values (AV). As shown in Figure 2-13, there is only a small 
difference in AUC values between the methods (AV and MV), with the MV being 
slightly better. This is consistent with molecules requiring only one (reasonable) 
conformation to be similar in shape in order to share biological activity. Comparing 
the AUC values obtained for conformations generated from SMILES with those for 
crystal structures shows only a little deterioration (Table 2-5). The logistic regression 
plots and ROC curves for both test sets (when using AV and MV methods with SD10 
and DT=0.65 and BOV=0.60) can be seen in Figure 2-14 and  Figure 2-15, 
respectively. Thus, using conformations generated from SMILES instead of crystal 
structures does not greatly affect the accuracy of the shape fingerprint method. This 
shows that the method can be successfully used even when the bioactive conformation 
of the ligand is not known.   
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1A) 
 
1B) 
 
2A) 
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2B) 
 
Figure 2-13. Heatmaps with AUC values for MV (A) and AV (B) methods for Test 
Set 1 (1) and Test Set 2 (2) when using SD10 with various DT and BOV. 
1A) 
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1B) 
 
2A) 
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2B) 
 
Figure 2-14. Logistic regression plot for Test Set 1 (1) and Test Set 2 (2) using AV 
(A) and MV (B) methods for SD10 with DT=0.65 and BOV=0.60. 
 
1A) 
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1B) 
 
2A) 
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2B) 
 
Figure 2-15. The ROC curves for Test Set 1 (1) and Test Set 2 (2) when using AV 
(A) and MV (B) methods for SD10 with DT=0.65 and BOV=0.60.  
 
Table 2-5. The comparison of the AUC values of both test sets when using 
conformations generated from SMILES and crystal structures for SD10 with DT=0.65 
and BOV=0.60.  
 CONFORMATIONS CRYSTAL STRUCTURES 
AV MV 
TEST SET 1 0.61 0.61 0.64 
TEST SET 2 0.77 0.78 0.85 
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2.5.5. Comparison with 2D fingerprints and scaffold hopping 
As already mentioned, shape fingerprints neglect the chemical structure of the 
molecule. Therefore, they should complement the 2D fingerprint methods that are 
exclusively dependent on the chemical structure. In order to compare and contrast the 
two approaches, 2D fingerprints for both test sets were generated and compared using 
a Similarity Tanimoto. The calculated AUC values are shown in Table 2-6. The AUC 
values are higher when using 2D fingerprints for both test sets. However, considering 
that shape fingerprints do not use any chemical information of the molecules but only 
their shape, the slightly worse AUC values than for well-established methods is not 
too surprising.  
Table 2-6. Comparison of the AUC values for different fingerprint methods. In the 
case of shape fingerprints, values obtained for SD10 with DT=0.65 and BOV=0.60 
are shown. 
 FINGERPRINT METHOD 
 MACCS166 Path Tree Circular Shape 
Fingerprints 
TEST SET 1 0.74 0.67 0.69 0.69 0.64 
TEST SET 2 0.94 0.94 0.94 0.97 0.85 
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Figure 2-16. Plot showing ST scores obtained by both methods: Shape Fingerprints 
and MACCS166 fingerprints (2D fingerprints) for each comparison in Test Set 1 (top) 
and Test Set 2 (bottom). Points in red correspond to compound pairs that share 
biological activity those in blue do not. 
To investigate the complementarity between the two fingerprint types, the Tanimotos 
between pairs of molecules have been computed with both methods. These are plotted 
against one another in Figure 2-16. Many pairs of molecules with shared biological 
activity (colored red) have high similarity according to both methods, which is 
unsurprising. There are a small number of examples of molecules with low shape 
similarity but high 2D fingerprint similarity that share biological activity but most 
interestingly, there are also a small number with high shape similarity and relatively 
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low 2D fingerprint similarity.  The orange box on each of the plots in Figure 2-16 
highlights these examples. These are connections that represent scaffold hopping. 
One example of a pair of structures for each of the test sets is shown in Figure 2-17 
and Figure 2-18. In Figure 2-17, an example of a connection between a neuraminidase 
molecule that contains an aromatic core and one with a monosaccharide core is a very 
clear example of scaffold hopping between inhibitors that are likely to have different 
physical properties while the indole and ortho-substituted phenol pair in Figure 2-18 
show that these ring-opening scaffold hops can also be detected by shape fingerprints. 
A) 
 
B) 
 
Figure 2-17. The structures of molecules binding to Neuraminidase with pdb codes: 
1b9s (A) and1nsc (B). 
A) 
 
B) 
 
Figure 2-18. The structures of molecules binding to Tryptophan Synthase with pdb 
codes: 1k7e (A) and1tjp (B). 
The combination of shape and 2D fingerprints was also investigated. Logistic 
regression (using the combination of Test Set 1 and Test Set 2) linked values of FT 
(for shape fingerprints) and Similarity Tanimoto (for 2D fingerprints) with the 
likelihood of shared activity. When two molecules are compared, the highest 
probability (either shape or 2D) was selected in each case. In this way, the calculated 
AUC values improved for Test Set 1 to 0.74 and Test Set 2 to 0.94. The two methods 
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provide useful complementarity and combine the ability to make useful connections 
between molecules with shared chemical structures and those with shared shape and 
thus permit both clustering and scaffold hopping. 
2.6. Conclusions 
The chapter details the implementation and validation of the shape fingerprints 
method, a promising method for describing and comparing molecular shape. The 
method is able to distinguish subsets of compounds that share biological activity with 
good levels of accuracy, considering that only the shape of molecules is considered; 
no other features are represented in these calculations. The obtained AUC values were 
0.64 and 0.85 for Test Set 1 and Test Set 2, respectively. This suggests that shape is a 
strong influence on biological activity, as envisaged by the lock-and-key concept. 
Shape fingerprints are a useful method to apply this concept and are able to group 
compounds that are likely to share biological activity. The AUC analysis (as well as 
examination of logistic regression plots) has permitted the identification of the best 
performing Shape Database: SD10. The optimum settings involve DT set to 0.65 and 
BOV to 0.60. The Shape Database 10 performs well when crystal structures are used 
but also in case of conformations of ligands generated form SMILES with AUC values 
of 0.61 and 0.61 (AV and MV method respectively) for Test Set 1and 0.77 and 0.78 
for Test Set 2, which is comparable with 2D fingerprint methods. However, the ability 
of shape fingerprints to find molecules similar in shape which could not be found using 
2D fingerprints (the different chemistry) shows great potential in scaffold hopping.  
The best Shape Database can be accessed via our GitHub repository: 
https://github.com/LeachResearchGroup/ShapeFingerprints.  
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Chapter 3  
 
 
Shape Multipoles 
 
 
 
 
 
3.1. Introduction 
Shape multipoles71 is a fast computational method that can be used to describe the 
shape of compounds using only numbers. This comes with many advantages including 
low storage needs and fast comparisons that require only simple mathematical 
operations. The shape multipoles71 method describes the distribution of a molecule’s 
volume using centroids and multipoles (monopole, dipoles, quadrupole, octupole 
moments), which are computed using a Gaussian description of a molecule.70 Like in 
physics, where the electric dipole moment is used to describe the distribution of charge 
within a system, as shown in Equation 3-1, the analogous equation can be written 
based on Gaussian density (Equation 3-2). 
Equation 3-1. the electric dipole moment, defined as the first order of multipole 
expansion, where ρelec is electrostatic charge density and r is the Cartesian coordinates 
of a point. 
𝑝 = න 𝑟𝜌௘௟௘௖ (𝑟)𝑑𝑟 
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Equation 3-2. The first order term in the shape multipole expansion, where V is 
defined as the Gaussian volume, rα, rβ, rγ, etc. are the Cartesian coordinates of a point 
and ρg is the Gaussian density of a molecule. 
𝑆ఈ
(ଵ) =
1
𝑉
 න 𝑟ఈ𝜌௹
௚ (𝑟)𝑑𝑟 
The Gaussian volume from Equation 3-2 is the zeroth order term describing the shape 
(monopole) and can be defined as in Equation 3-3, showing its independence from a 
change in origin for the coordinate system. 
Equation 3-3. The zeroth moment, the Gaussian volume. 
𝑉 = න 𝜌௹
௚ (𝑟)𝑑𝑟 
However, the higher order moments should not be defined before specifying the origin 
of the molecule, its centroid. The first order moment (Equation 3-2) can be therefore 
adjusted (Equation 3-4) to indicate its dependency on the centre of the molecule. The 
choice of S(1) as an origin with coordinates R=(X,Y,Z), leads to vanishing  of the first 
order moment. Now, having defined the centroid of the molecule, there can be defined 
higher order moments.  
Equation 3-4. The first order moment.   
𝑆(ଵ)ᇱ =
1
𝑉
 න 𝑟ᇱ𝜌௹
௚ (𝑟)𝑑𝑟 =  𝑆(ଵ) − 𝑅 
Higher order terms can be defined as in Equation 3-5, which can be simply 
transformed into second (Equation 3-6) and third (Equation 3-7) order of the shape 
multipole expansion, which are known as the shape quadrupole and shape octupole, 
respectively. 
Equation 3-5. Shape Nth order multipole.  
𝑆ఈభఈమ…ఈ೙
(௡) =
1
𝑉
 න 𝑟ఈభ𝑟ఈమ … 𝑟ఈ೙𝜌௹
௚ (𝑟)𝑑𝑟 
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Equation 3-6. Shape Quadrupole, the second order moment. 
𝑆ఈఉ
(ଶ) =
1
𝑉
 න 𝑟ఈ𝑟ఉ𝜌௹
௚ (𝑟)𝑑𝑟 
Equation 3-7. Shape Octupole, the third order moment.  
𝑆ఈఉఊ
(ଷ) =
1
𝑉
 න 𝑟ఈ𝑟ఉ𝑟ఊ𝜌௹
௚ (𝑟)𝑑𝑟 
As can be seen in the Figure 3-1 and also based on the Equation 3-6, the quadrupole’s 
components (Qx, Qy, Qz) describe how the matter is distributed along the three 
orthogonal axes such that linear molecules (such as 1,3,5-hexatriyne) have one large 
component, flat molecules (like benzene) have two large components and spherical 
molecules (like Buckminsterfullerene) have three large components. Their octupole 
moments are really small or equal to zero. This suggests that octupoles are more 
appropriate to identify asymmetric spatial distribution of shape, being almost 
neglected in symmetric molecules. However, the shape quadrupoles look the same for 
two enantiomers. As shown in Figure 3-1, some of the octupole components for (R)-
(+)-thalidomide (E) and (S)-(−)-thalidomide (F) have the same value but different sign, 
which indicate the differences in shape of those two enantiomers and indicates that 
shape octupoles describe some of the unsymmetrical distribution of matter in a 
molecule. 
A) 
 
B) 
 
C)  
 
<Quadrupoles> 
4.74, 4.68, 4.66 
<Octupoles> 
0.01, 0.00, -0.00, -
0.00, 0.00, -0.00, -
0.00, -0.01, 0.00, -
0.00 
 <Quadrupoles> 
1.59, 1.59, 0.62 
<Octupoles> 
0.00, 0.00, -0.00, -
0.00, -0.00, 0.00, 
0.00, -0.00, -0.00, -
0.00 
 <Quadrupoles> 
5.39, 0.62, 0.62 
<Octupoles> 
0.00, 0.00, 0.00, 
0.00, -0.00, 0.00, 
0.00, 0.00, -0.00, 
-0.00 
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D) 
 
E) 
 
 
<Quadrupoles> 
8.78, 1.63, 1.15 
 
<Octupoles> 
1.81, 0.30, 0.29, -1.53, -0.73, -
1.39, -0.08, 1.17, 0.01, -0.24 
 <Quadrupoles> 
8.78, 1.63, 1.15 
 
<Octupoles> 
1.82, 0.30, -0.29, -1.52, 0.71, -
1.39, 0.08, 1.17, 0.01, 0.24 
Figure 3-1. Example of calculated shape quadrupoles for Buckminsterfullerene (A) 
with three almost equal quadrupole components, benzene (B) with two components 
slightly greater than the third and hexa-1,3,5-triyne (C) with only one outstandingly 
higher quadrupole component and shape octupoles for (R)-(+)-thalidomide (D) and 
(S)-(−)-thalidomide (E). 
3.2. Components of shape multipoles 
Shape multipoles were computed using the Shape toolkit provided by Openeye78 for a 
few chosen molecules from Test Set 1 (as described in chapter 2). The reason for this 
was to examine the components of shape quadrupoles and their ability to distinguish 
similar molecular shape.  
The shape multipoles method performs surprisingly well considering the amount of 
components it includes. Hence, the components of shape quadrupoles and octupoles 
for molecules with similar shape, shown in Figure 3-2 were compared and the values 
were stored in Table 3-1. This suggests that the components of shape quadrupoles are 
capable of characterizing the broad shape features of molecules. The corresponding 
components do not deviate much from each other for very similar shapes of molecules. 
However, shape octupoles are not so straightforward to interpret but likely carry more 
specific and accurate information about the shape of compounds. 
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2brb 2brg 
  
2brh 2brm 
Figure 3-2. The chemical structures of selected Checkpoint kinase (Chk1) ligands. 
Table 3-1. Shape quadrupoles for some ligands that bind to Checkpoint kinase (Chk1).  
Ligand Q1 Q2 Q3 
2brb 9.25 4.40 0.91 
2brg 9.73 4.17 0.89 
2brh 9.90 4.75 0.78 
2brm 9.26 4.25 0.92 
 
3.3. Test Sets 
To evaluate the performance of shape multipoles, we used three test sets: 1) a set 
described by Taylor et al.79, which was devised to test pharmacophore models and 
consists of 10 sets of ligand-protein complexes 2) a group from the Astex diversity 
set80, which includes 45 molecules binding to 4 selected proteins and 3) a set of 4 
groups of protein-ligand complexes from a set described by Head et al.87  
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Shape octupoles were generated for every compound in three test sets. Molecules were 
compared with each other based on the calculated multipoles. The Euclidean distance 
between shape octupoles were used to determine the similarity between the shapes of 
each structure. Euclidean distance is equal to 0 for the most similar compounds but 
has no upper bound for dissimilar molecules.  
The performance of the method was evaluated using logistic regression and AUC 
values from ROC plots, which were generated using R.82 Logistic regression was used 
to link the Euclidean distance with the proportion of structures that bind to the same 
protein, which corresponds to the likelihood of the two molecules sharing biological 
activity. Ideally, the Euclidean distance values would be low for all molecules that 
bind to the same protein and high for compounds which do not share activity.  
A) 
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B) 
 
C) 
 
Figure 3-3. Logistic regression plots for 3 Test Sets when using ∆Octupoles: Test Set 
1 (A), Test Set 2 (B), Test Set 3 (C). 
The plots in Figure 3-3 show the distribution of Euclidean distance values for 
molecules that share activity (upper histogram) and those that do not (lower 
histogram). The logistic regression plot for shape octupoles suggests that they do not 
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provide a good distinction. Only in case of Test Set 2, the probability of two molecules 
that bind to same protein having low ∆Octupoles reaches almost 80%. However, that 
might be the result of the wide range of the Euclidean distance values.  
A) 
 
B) 
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C) 
 
Figure 3-4. ROC curves for 3 Test Sets when using ∆Octupoles: Test Set 1 (A), Test 
Set 2 (B) and Test Set 3 (C). 
The ROC curve is a fundamental tool for diagnostic test evaluation. In a ROC curve 
the true positive rate (Sensitivity) is plotted as a function of the false positive rate (100-
Specificity) for different cut-off points of a parameter. Each point on the ROC curve 
represents a sensitivity/specificity pair corresponding to a particular decision 
threshold. The area under the ROC curve (AUC) is a measure of how well a method 
is able to distinguish molecules that share biological activity from those that do not. A 
perfect method would achieve an AUC value of 1, a completely random method 0.5. 
Test Set 1 results in an AUC value of 0.54, which is not much better from a random 
distribution. Higher results were obtained for Test Set 2 – 0.81 and Test Set 3 – 0.68. 
This is slightly lower than the results obtained using the shape fingerprint method: 
0.64 and 0.85 for Test Set 1 and 2, respectively. Test Set 3 was not used with the shape 
fingerprint method as it produced bit strings with too low (or even zero) bit density, 
therefore cannot be compared here. 
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3.4. Enantiomers 
In order to check whether the shape multipole method could be applicable to find 
differences in shape between enantiomers, three sets were used that were extracted 
from the CHEMBL database88 based on their measured IC50 values: the ligands of 
acetylcholinesterase (AChE), human ether-a-go-go-related gene potassium channel 1 
(hERG) and dipeptidyl peptidase IV (DPP-IV). These comprised 448, 190 and 136 
pairs of enantiomers, respectively. 
Conformations of all molecules were generated by OMEGA83 from canonical 
SMILES with default settings. The structures that failed the generation process due to 
unspecified stereochemistry had been rejected. All the conformations were optimized 
using Szybki78 before calculating shape multipoles.  
3.4.1. Human ether-a-go-go-related gene potassium channel 1 
(hERG)  
The set of compounds, inhibitors of hERG, was downloaded from the CHEMBL 
database88 and were selected by the requirement to have a measured IC50. The 
enantiomer pairs were found by text manipulation. Initially, the set consisted of 448 
pairs of enantiomers out of which, duplicates and those without any IC50 values have 
been discarded from the further analysis leaving 105 distinct pairs. For those pairs the 
shape multipoles were calculated, both shape quadrupoles and octupoles. As 
mentioned previously, the shape quadrupoles for any enantiomer pairs are either the 
same or very similar, the further analysis was focused on comparing the shape 
octupoles of each pair. The plot in the Figure 3-5 shows the relationship between the 
difference in octupoles and the change of pIC50 for each pair of compounds.  
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Figure 3-5. The graph showing the ∆pIC50 as a function of ∆Octupoles for 
enantiomer pairs from hERG dataset. 
In the Figure 3-5, it is noticeable that the division between pairs with only one 
stereocentre and more than one is not clear. There are some points that particularly 
stand out and will be discussed below. Those are marked in red, yellow and blue circles 
in the plot in the Figure 3-5. 
In the red circle in Figure 3-5, there are enantiomer pairs with high ∆pIC50 and a 
medium difference in octupoles. As shown in the Figure 3-6, the difference in the 
octupoles is not as high as would be expected based on the difference in pIC50 these 
pairs have quite similar shapes.  
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2A) 
 
2B) 
 
Figure 3-6. The structures of enantiomer pairs: CHEMBL498260 (1A) and 
CHEMBL55826 (1B); CHEMBL239299 (2A) and CHEMBL239724 (2B). 
In the blue circle in Figure 3-5, there are enantiomer pairs with a medium ∆pIC50 and 
quite low difference in octupoles, which, as in the examples above, could be explained 
by similarities in overall shape of these particular enantiomer pairs. This can be seen 
in the Figure 3-7. 
1A) 
 
1B) 
 
2A) 
 
2B) 
 
3A) 
 
3B) 
 
Figure 3-7. The structures of enantiomer pairs: CHEMBL550471 (1A) and 
CHEMBL556648 (1B); CHEMBL1200749 (2A) and CHEMBL2447962 (2B); 
CHEMBL1091777 (3A) and CHEMBL1091778 (3B). 
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In the yellow circle in Figure 3-5, are enantiomer pairs with low ∆pIC50 and high 
difference in octupoles. As shown in the examples in the Figure 3-8, the differences 
in shapes of these pairs are not that great as is indicated by the calculated octupole 
difference.  
1A) 
 
1B) 
 
2A) 
 
2B) 
 
Figure 3-8. The structures of enantiomer pairs: CHEMBL272637 (1A) and 
CHEMBL429761 (1B); CHEMBL3124968 (2A) and CHEMBL3127672 (2B). 
The most extreme values of ∆Octupoles are obtained for enantiomer pairs with more 
than one stereocentre. As can be seen in the Figure 3-5, there are two pairs with 
∆Octupole equal to 76.58 and 62.46: CHEMBL1079823 and CHEMBL1079824 pair 
and CHEMBL2010844 and CHEMBL2010845 pair, respectively. This is mostly 
caused by the flexibility of the molecules - enantiomers have different shapes after 
optimization process, which results in high difference in octupoles.   
1A) 
 
1B) 
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2A) 
 
2B) 
 
Figure 3-9. The structures of enantiomer pairs: CHEMBL1079823 (1A) and 
CHEMBL1079824 (1B); CHEMBL2010844 (2A) and CHEMBL2010845 (2B). 
3.4.2. Acetylcholinesterase (AChE)  
The set of AChE ligands from the CHEMBL database88 consisted of 190 pairs, which 
were found by simple text manipulation. The pairs without specified IC50 values and 
those that were considered as duplicates have been removed, leaving 27 distinct pairs.  
 
Figure 3-10. The graph showing the ∆pIC50 as a function of ∆Octupoles for 
enantiomer pairs from AChE dataset. 
There is a clear distinction between pairs with one stereocentre and those with more 
than one stereocentre in the AChE set, visible in Figure 3-10. However, as the ∆pIC50 
tends to have a higher value for pairs with more stereocentres, the difference in 
Octupoles does not grow linearly with it. There is one outstanding point on the plot, 
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marked in the red circle, with ∆pIC50 = 0.93 and ∆Octupoles = 8.68. The structures 
of the pair can be seen in Figure 3-11. It is worth noting that this particular pair has 
quite a high difference in Quadrupoles (1.09), which usually gives values much closer 
to 0 for two enantiomers.  
A) 
 
B) 
 
Figure 3-11. The structures of enantiomer pair: CHEMBL470715 (A) and 
CHEMBL490359 (B). 
The most extreme value of ∆Octupoles is obtained for enantiomer pair with more than 
one stereocentre, as it can be seen in the Figure 3-5.The value of ∆Octupole is equal 
to 161.03 for CHEMBL540178 and CHEMBL556581 pair (Figure 3-12). Similarly 
as in other cases, the generated and optimized conformations differ in shape for each 
enantiomer due to flexibility of compounds and therefore comparing them resulted in 
high ∆Octupole value.  
1A) 
 
1B) 
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Figure 3-12. The structures of enantiomer pair: CHEMBL540178 (1A) and 
CHEMBL556581 (1B). 
3.4.3. Dipeptidyl peptidase IV (DPP-IV) 
The set of DPP-IV ligands initially consisted of 136 pairs, which were found by text 
manipulation. After removing duplicate pairs without specified bioactivity data, which 
was essential for further analysis, there were 34 distinct pairs left. Shape octupoles 
were calculated for them and the relation between the difference in octupoles and the 
difference in pIC50 was studied.  
 
Figure 3-13. The graph showing the ∆pIC50 as a function of ∆Octupoles for 
enantiomer pairs from the DPP-IV dataset. 
As in the case of the AChE set, the plot in Figure 3-13 has a noticeable distinction 
between pairs with different numbers of stereocentres. With one exception, generally 
for pairs with only one stereocentre the difference in Octupoles grow almost linearly 
with the ∆pIC50.   
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A) 
 
B) 
 
Figure 3-14. The structures of enantiomer pair: CHEMBL3329627 (A) and 
CHEMBL3329694 (B). 
The exception is the pair of enantiomers marked in red box on the plot in Figure 3-13, 
with the structures visible in Figure 3-14.  
The highest value of ∆Octupoles (26.27) has a pair of enantiomers: CHEMBL428936 
and CHEMBL399348. Such difference could be a result of flexibility of cyclic rings 
(Figure 3-15). 
1A) 
 
1B) 
 
Figure 3-15. The structures of enantiomer pair: CHEMBL428936 (1A) and 
CHEMBL399348 (1B). 
3.5. Conclusions 
The shape multipole method is a fast computational method to describe the shape of 
molecules by using only numbers and therefore it requires low storage needs and 
comparison is performed by simple mathematical operations. To describe the shape, 
it uses only 13 values (3 quadrupole components and 10 octupole components). While 
the quadrupole components describe the distribution of matter in a system along the 
axes x, y, z, and therefore do not contain too specific information, the octupole 
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components describe the deviations of matter from axes in a system more accurately 
and thus can explain the differences in shape and activity between enantiomers.  
The shape multipoles method performs surprisingly well in grouping the compounds 
based on shared biological activity, considering the amount of components it includes. 
The obtained AUC values of 0.54, 0.81 and 0.68 for Test Set 1, Test Set 2 and Test 
Set 3, respectively are slightly lower than the results obtained using the shape 
fingerprint method: 0.64 and 0.85 for Test Set 1 and 2, respectively (Test Set 3 was 
not used).  
The investigation of using shape multipoles in order to find differences in shape 
between enantiomers showed potential, however requires better comparison metrics 
in order to be more effective. 
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Chapter 4  
 
 
Application of shape fingerprints 
 
 
 
 
 
4.1. Introduction  
In order to be useful, the method needs to show a good performance in addressing 
some scientific problems. Without applying it, and having proved good performance, 
to real problems that affect the chemistry world, it is hard to recommend the approach 
as a solution. This would diminish the likelihood of the shape fingerprint method being 
used. Consequently, in this chapter a few of the possible applications of the shape 
fingerprint method will be explored. These include solubility predictions, virtual 
screening or simply grouping compounds with shared biological activity.  
4.2. DUD-E diverse set 
The quantitative assessment of performance of a lot of computational methods remains 
challenging.89 The Directory of Useful Decoys (DUD) was designed to measure how 
known ligands rank versus a set of decoy molecules.90 Here, the set from the DUD-E 
database was used in an alternative way. The collection of decoys was not included 
and only actives were taken into consideration. The idea behind this was to investigate 
the ability of the shape fingerprints method to group compounds binding to different 
targets, similarly as in chapter 2, where the validation of the method was based on the 
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ability to group compounds with similar biological activity. However, the set 
presented here is much larger than used previously. This should examine how well the 
approach works on various size sets with more shape diversities.  
4.2.1. Results 
The DUD-E diverse set consists of 8 targets: serine/threonine-protein kinase AKT 
(AKT1), beta-lactamase (AMPC), cytochrome P450 3A4 (CP3A4), C-X-C chemokine 
receptor type 4 (CXCR4), the glucocorticoid receptor (GCR), human 
immunodeficiency virus type 1 protease (HIVPR), human immunodeficiency virus 
type 1 reverse transcriptase (HIVTR) and kinesin-like protein 1 (KIF11). It consists of 
290, 48, 166, 39, 258, 527, 330 and 116 actives, respectively (which is 1774 ligands 
in total) in AKT1, AMPC, CP3A4, CXCR4, GCR, HIVPR, HIVRT and KIF11, 
respectively.  
The structures of molecules were taken from the DUD-E webpage,90 provided as 
structure-data files (SDF). The shape fingerprints were generated for each structure 
using Shape Database SD10 with DT = 0.65. A bit On value equal to 0.60 was applied, 
exactly as suggested in the previous chapter to maximize the performance of the 
method. The ability to group ligands was analysed based on plots (ROC curve and 
logistic regression) produced in R.82 
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Figure 4-1. The ROC curve for the DUD-E diversity set. 
 
Figure 4-2.  Logistic regression plot for the DUD-E diversity set.  
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As shown in the Figure 4-1, the AUC value calculated for the DUD-E diversity set is 
equal to 0.55. This is a little bit lower value than the ones obtained in previous study 
in chapter 2 (0.64 and 0.85 for Test Set 1 and Test Set 2, respectively). However, the 
size of the set presented here is much greater and therefore a value in this range could 
have been expected. The large jump in the ROC curve is possibly caused by a high 
percentage of compounds with dissimilar shape yet shared biological activity. The 
probability curve from the logistic regression plot, in the Figure 4-2, reaches the value 
of 0.8 and it reveals that for FT above 0.5 there is greater than 50% chance of shared 
biological activity. This behaves slightly better than in the case of Test Set 1 used in 
evaluation of shape fingerprint method and worse than Test Set 2 described in chapter 
2.  
4.3. Virtual Screening 
Virtual screening is a computational technique used in drug discovery to search 
libraries of small molecules in order to identify those structures which are most likely 
to bind to a drug target, typically a protein, receptor or enzyme.90,91 The virtual 
screening techniques are rated based on their ability to retrieve a small group of actives 
from a large collection of structures with similar physicochemical properties but 
dissimilar 2D topology – decoys.90  
4.3.1. Results 
As virtual screening is a common technique in the drug design process,29 it was of 
great interest to check the performance of the shape fingerprint method in it. With the 
purpose to test whether the shape fingerprint method is able to distinguish the 
molecules that are active from those that are not, three sets from DUD-E were 
chosen.90 These sets include: C-X-C chemokine receptor type 4 (CXCR4), Beta-
lactamase (AMPC) and Catechol O-methyltransferase (COMT). The sets contain 40, 
48 and 41 actives, respectively and a series of decoys. The shape fingerprints were 
generated for these sets using Shape Database SD10 with DT = 0.65 and BOV = 0.60. 
The molecules were compared with each other, resulting in Fingerprint Tanimoto 
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values. The values were grouped into those arising from comparison of active 
compounds and those from the comparison of inactives. Based on that, ROC curves 
were produced for the three sets using R studio.92  
 
Figure 4-3. The ROC curve for the CXCR4 set. 
 
Figure 4-4. The ROC curve for the AMPC set. 
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Figure 4-5. The ROC curve for the COMT set. 
The shape fingerprint method performed relatively well, considering the size of the 
sets and the high ratio of decoys per ligand. The AUC values obtained from the ROC 
curve are 0.57, 0.66 and 0.62 for CXCR4, AMPC and COMT sets, respectively. This 
gives opportunities that shape fingerprints could be successfully used as a ligand-
based virtual screening technique. 
4.4. Aqueous Solubility 
Solubility prediction has a great importance in the pharmaceutical industry because of 
its implications in the formulation of drugs and in drug absorption.93 The solubility of 
compounds depends on their physical and chemical properties. The interaction of 
solutes with water and its crystallinity play important roles in determining the 
solubility of a compound.94  
 Many methods have been developed to estimate aqueous solubility using various 
physical properties of compounds. The most often used, and also the simplest model, 
is the general solubility equation (GSE), as in Equation 4-1, which was proposed by 
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S. Yalkowsky.95,96,97 The equation shows that the solubility of a compound can be 
calculated from the melting point (MP) and octanol-water partition coefficient (logP) 
of a compound. The logP values can be either obtained experimentally or calculated 
using scientific software e.g. MOE.98  
Equation 4-1. General Solubility Equation, where SW is aqueous solubility, MP is the 
melting point and logP is the octanol-water partition coefficient of the compound. 
𝑙𝑜𝑔 𝑆ௐ = 0.5 − 0.01(𝑀𝑃 − 25) − 𝑙𝑜𝑔𝑃 
This model, however, requires experimental data and therefore cannot be applied to 
molecules without such data or new compounds for which those values have not been 
measured, yet. Therefore, computational methods able to accurately predict solubility 
are in high demand. Based on the GSE, instead of using melting point which is 
dependent on the shape of molecules (to the extent that they influence packing in the 
solid state), it was of great interest to apply shape fingerprints.  
4.4.1. Results 
All the data for solubility studies were collected from various databases and literature. 
The data includes information from large solubility datasets: PhysProp,99 Reaxys 
Databases100 and Yalkowsky’s Handbook of Aqueous Solubility,101 as well as many 
literature published solubility datasets.102–116  For molecules without any SMILES, 
these were generated using ChemCell,117 ChemSpider,118 ChemDraw or ChemIDPlus. 
The dataset contained 102821 measurements of solubility and/or melting points. After 
taking only unique SMILES strings the number reduced to 94955. Measurements of 
solubility or melting points that had “less than” or “more than” prefixes were excluded 
from the dataset and the highest value in ranges of melting point was taken and the 
lowest value for solubility. The reason for that was to allow prediction based on the 
most stable polymorph.  
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4.4.1.1. Training and Test Set to predict solubility – Shape Database 
10 
The dataset was divided into 1) a set containing logS values 2) compounds having 
measured MP values 3) compounds with measured values of both logS and MP. The 
latter set with measured values of both logS and melting point was used as the most 
suitable for the solubility prediction and its comparison to the GSE model. The set of 
compounds (945 molecules) was divided into two sets: training (90%) and test set 
(10%). The shape fingerprints were generated for both sets (training and test) using 
SD10 and DT= 0.65 and BOV = 0.60. This Shape Database was suggested as 
producing the best results in chapter 2. The independent values were selected to be 
calculated logP (computed in MOE)98 and all the bits from the generated shape 
fingerprint string. The applied method was ‘Enter’, which means that all independent 
variables are entered into the equation in one step. The model built using the training 
set was stored (Equation 4-2, Table 4-1) and used on the 95 molecules of the test set 
to predict their logS values. The model built with clogP and experimental MP values 
was used as a benchmark (adjusted R2 = 0.612). The obtained results were compared 
to experimental values of logS as well as those predicted in MOE98 in the Table 4-2. 
Equation 4-2. The linear regression model used for prediction of solubility. The 
coefficients for each bit can be found in the table below.  
𝑙𝑜𝑔 𝑆ௐ = −2.140 − 0.427𝑙𝑜𝑔𝑃 + 0.450𝐵𝑖𝑡1 − 0.038𝐵𝑖𝑡10 + ⋯ 
 
Table 4-1. The table of constant and coefficients used for solubility prediction. Some 
bits (not listed here) are constants or have missing correlations.  
MODEL UNSTANDARDIZED 
COEFFICIENTS 
B Std. Error 
(CONSTANT) -2.140 0.259 
LOGP -0.427 0.030 
BIT1 0.450 0.565 
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BIT10 -0.038 0.244 
BIT12 15.216 13.595 
BIT14 -0.433 6.037 
BIT17 55.307 22.637 
BIT18 -0.716 1.652 
BIT22 -16.848 12.075 
BIT24 14.071 27.932 
BIT26 -1.613 6.214 
BIT30 0.066 0.199 
BIT32 0.085 0.195 
BIT36 0.352 0.221 
BIT40 0.498 0.248 
BIT45 -59.117 23.955 
BIT50 4.157 5.203 
BIT51 108.107 37.984 
BIT52 -3.234 3.443 
BIT54 -1.072 2.497 
BIT56 0.038 0.621 
BIT58 -0.538 0.213 
BIT60 -0.149 0.253 
BIT62 0.032 0.266 
BIT64 0.062 0.604 
BIT66 -4.860 38.180 
BIT70 -6.849 38.975 
BIT76 -2.325 14.958 
BIT81 -25.653 12.229 
BIT82 -0.035 1.238 
BIT83 11.325 35.828 
BIT85 0.315 0.206 
BIT87 -38.310 24.825 
BIT89 -4.293 6.423 
BIT90 -4.127 29.493 
BIT91 -54.286 16.998 
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BIT95 -23.864 17.144 
BIT96 -12.968 37.503 
BIT98 7.391 7.500 
BIT100 -32.690 14.413 
BIT102 -0.504 0.234 
BIT104 -0.207 1.420 
BIT106 3.908 3.329 
BIT108 -57.546 30.162 
BIT110 -10.662 8.545 
BIT112 0.277 0.679 
BIT114 0.350 0.979 
BIT116 -3.137 5.102 
BIT118 -6.980 24.101 
BIT121 43.058 49.661 
BIT122 -11.305 5.329 
BIT135 -10.339 5.360 
BIT139 -3.934 8.544 
BIT141 -5.110 12.954 
BIT142 -0.104 0.706 
BIT143 -13.364 11.337 
BIT146 0.310 0.294 
BIT148 0.512 0.252 
BIT152 0.077 0.308 
BIT154 -0.700 0.940 
BIT155 -13.962 8.102 
BIT156 -12.222 16.736 
BIT164 24.663 38.976 
BIT170 -0.751 0.976 
BIT171 -24.871 60.005 
BIT172 27.463 23.111 
BIT180 -0.280 0.530 
BIT182 -1.040 1.329 
BIT184 -0.526 0.264 
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BIT186 1.277 1.042 
BIT188 -1.946 0.951 
BIT196 20.175 20.918 
BIT198 63.068 31.065 
BIT200 1.055 6.689 
BIT210 53.209 35.716 
BIT211 25.563 8.271 
BIT212 -19.575 15.010 
BIT216 1.224 0.470 
BIT219 -29.239 10.192 
BIT222 -1.472 5.557 
BIT223 -96.309 58.984 
BIT224 35.954 36.368 
BIT226 -0.403 49.922 
BIT228 34.538 21.153 
BIT230 -32.121 32.697 
BIT231 -35.265 12.060 
BIT232 -34.718 20.689 
BIT233 54.616 31.301 
BIT234 -3.993 4.812 
BIT236 -1.981 7.034 
BIT237 6.938 34.962 
BIT238 14.164 32.404 
BIT241 -73.142 41.727 
BIT242 27.264 19.186 
BIT244 0.031 1.725 
BIT248 2.843 2.742 
BIT251 -78.610 65.710 
BIT254 6.675 8.863 
BIT256 11.111 6.737 
BIT258 -0.073 0.210 
BIT260 -0.312 0.242 
BIT266 77.324 35.587 
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BIT271 -36.416 16.404 
BIT273 -33.929 13.445 
BIT275 6.173 8.154 
BIT276 -1.632 1.490 
BIT277 18.698 9.128 
BIT278 -1.752 6.751 
BIT279 -0.011 21.719 
BIT282 66.805 21.526 
BIT283 0.247 2.241 
BIT286 16.796 7.158 
BIT289 6.238 39.858 
BIT290 12.659 4.512 
BIT292 -38.638 31.352 
BIT293 -20.478 11.007 
BIT298 160.230 68.863 
BIT301 6.828 6.031 
BIT303 0.238 0.383 
BIT305 -37.211 17.372 
BIT307 -0.139 0.317 
BIT309 0.945 0.538 
BIT311 0.313 1.225 
BIT313 0.920 1.073 
BIT315 -2.538 1.375 
BIT318 -2.425 5.208 
BIT322 1.944 6.623 
BIT324 -2.777 1.368 
BIT326 -102.865 49.191 
BIT328 -0.621 1.275 
BIT330 -0.609 8.385 
BIT331 -56.697 35.842 
BIT332 -13.353 20.318 
BIT335 -6.050 10.167 
BIT337 28.584 18.549 
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BIT339 1.571 1.687 
BIT343 -1.534 2.011 
BIT345 -3.408 3.132 
BIT347 8.391 23.402 
BIT349 -5.736 18.625 
BIT353 -0.897 1.478 
BIT357 -70.835 41.312 
BIT359 -75.363 29.522 
BIT361 -40.632 50.047 
BIT373 0.102 0.298 
BIT375 21.408 12.062 
BIT377 0.340 0.458 
BIT382 -17.031 20.233 
BIT384 -25.139 24.973 
BIT390 -22.209 11.659 
BIT394 -12.502 13.397 
BIT397 30.690 29.705 
BIT398 77.154 46.105 
BIT400 -2.227 3.107 
BIT402 -2.002 3.064 
BIT406 -19.401 35.368 
BIT408 -13.621 42.432 
BIT410 6.244 26.800 
BIT413 6.263 15.838 
BIT414 -60.398 51.227 
BIT416 5.022 4.151 
BIT418 0.639 0.940 
BIT420 -0.491 0.929 
BIT422 -3.144 3.016 
BIT424 21.040 19.180 
BIT426 -20.310 39.636 
BIT427 144.522 72.619 
BIT428 -8.963 9.018 
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BIT431 28.504 18.983 
BIT432 0.598 0.507 
BIT434 0.013 0.412 
BIT436 49.215 50.656 
BIT438 -3.109 1.282 
BIT440 68.913 33.500 
BIT446 56.041 39.203 
BIT447 -121.916 54.209 
BIT449 0.810 1.267 
BIT450 -5.652 3.206 
BIT453 0.100 0.277 
BIT455 1.198 2.162 
BIT457 13.163 4.768 
BIT458 -18.746 17.552 
BIT461 -13.232 24.046 
BIT462 -29.683 36.545 
BIT463 22.749 15.935 
BIT467 -4.545 22.893 
BIT470 -2.315 1.604 
BIT472 64.730 45.585 
BIT473 23.767 13.416 
BIT475 -1.894 17.679 
BIT476 -29.894 21.066 
BIT479 8.883 26.827 
BIT482 -14.772 9.922 
BIT483 -42.324 22.849 
BIT484 -23.455 53.482 
BIT485 -0.004 0.800 
BIT493 3.189 8.405 
BIT495 19.164 19.644 
BIT497 -78.415 43.803 
BIT499 22.246 80.955 
BIT501 0.267 1.736 
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BIT505 1.218 4.416 
BIT506 97.580 42.207 
BIT507 40.542 68.341 
BIT508 119.132 44.827 
BIT509 -21.783 19.109 
BIT510 -5.268 4.630 
BIT512 -0.823 0.994 
BIT513 13.737 51.130 
BIT516 -10.053 10.494 
BIT517 8.360 7.415 
BIT519 68.383 22.741 
BIT521 -0.494 0.228 
BIT525 -2.416 6.168 
BIT526 -8.253 30.331 
BIT529 3.824 5.661 
BIT532 -0.360 1.259 
BIT533 0.399 1.078 
BIT536 -51.697 23.788 
BIT537 12.505 15.997 
BIT538 23.172 26.463 
BIT539 -13.221 10.205 
BIT540 59.977 68.899 
BIT541 -0.112 0.269 
BIT542 -22.167 13.504 
BIT543 -17.622 6.871 
BIT544 -0.335 2.787 
BIT545 -18.085 22.805 
BIT547 -111.956 41.659 
BIT548 48.690 17.332 
BIT549 -13.144 22.787 
BIT550 4.094 5.623 
BIT551 -7.517 21.034 
BIT552 -7.434 33.623 
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BIT554 10.608 37.121 
BIT555 -110.685 41.798 
BIT560 -0.484 1.206 
BIT562 1.646 1.469 
BIT564 0.259 0.253 
BIT565 -72.961 54.150 
BIT568 17.639 15.559 
BIT569 -73.238 51.805 
BIT572 -75.776 34.397 
BIT575 -0.192 2.351 
BIT578 -41.980 23.765 
BIT580 10.109 9.320 
BIT581 70.458 35.961 
BIT584 -24.472 25.270 
BIT586 55.233 26.261 
BIT587 1.123 18.077 
BIT588 0.078 1.313 
BIT590 1.728 4.979 
BIT591 -0.492 10.946 
BIT593 2.023 4.575 
BIT595 19.092 16.410 
BIT599 -28.539 23.155 
BIT600 -11.460 19.116 
BIT602 -1.057 1.062 
BIT604 -30.529 11.018 
BIT606 -38.094 25.873 
BIT610 40.970 33.068 
BIT611 -14.504 9.554 
BIT614 102.874 66.747 
BIT617 49.888 16.797 
BIT618 4.550 1.781 
BIT620 1.484 38.937 
BIT623 17.730 16.974 
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BIT624 21.777 61.291 
BIT625 -73.338 20.734 
BIT628 18.205 15.800 
BIT630 -21.544 43.972 
BIT631 -10.750 8.977 
BIT632 -0.641 2.969 
BIT633 -2.659 13.107 
BIT635 12.379 8.990 
BIT636 3.412 4.588 
BIT638 -28.762 58.877 
BIT640 -23.630 11.817 
BIT641 2.367 1.777 
BIT643 0.622 0.287 
BIT645 5.170 4.384 
BIT649 -38.197 14.449 
BIT650 0.504 5.276 
BIT652 -45.255 118.630 
BIT653 17.630 30.054 
BIT654 -42.579 21.406 
BIT656 -0.943 1.834 
BIT658 -17.746 9.461 
BIT660 0.181 0.314 
BIT664 -16.253 32.597 
BIT665 -3.833 9.831 
BIT667 -2.089 1.748 
BIT670 -2.689 1.831 
BIT672 -22.434 22.593 
BIT674 -0.269 0.239 
BIT676 -1.109 1.865 
BIT679 -0.174 0.317 
BIT681 -10.901 12.234 
BIT683 13.840 5.207 
BIT684 11.938 4.066 
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BIT689 -0.253 0.265 
BIT690 11.889 23.402 
BIT692 -0.121 0.323 
BIT695 -0.509 0.384 
BIT697 -20.465 14.120 
BIT698 -0.049 2.788 
BIT699 -8.031 9.606 
BIT703 3.605 7.575 
BIT704 0.215 1.239 
BIT705 -0.421 0.274 
BIT706 47.447 41.216 
BIT707 45.884 22.485 
BIT708 21.285 12.930 
BIT709 -61.282 39.672 
BIT710 -90.066 54.392 
BIT711 15.655 9.592 
BIT712 -22.063 17.700 
BIT713 166.089 63.720 
BIT715 0.561 2.377 
BIT717 -29.816 30.397 
BIT718 -17.824 28.303 
BIT721 -0.367 0.421 
BIT723 -4.332 8.099 
BIT725 3.119 2.570 
BIT727 -0.043 1.282 
BIT728 -56.798 26.172 
BIT729 53.625 38.742 
BIT732 64.354 41.108 
BIT736 -0.362 0.636 
BIT738 9.713 4.044 
BIT739 2.752 2.670 
BIT740 -15.217 4.766 
BIT741 11.315 21.126 
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BIT742 -11.613 4.484 
BIT744 0.182 2.896 
BIT746 34.190 21.169 
BIT747 -29.231 17.688 
BIT748 -12.813 4.161 
BIT749 8.442 9.794 
BIT750 12.109 34.250 
BIT752 30.048 20.411 
BIT753 -0.051 1.474 
BIT754 -1.686 4.463 
BIT755 9.107 17.176 
BIT756 15.010 7.439 
BIT759 2.263 4.121 
BIT760 -85.591 104.228 
BIT762 4.179 1.920 
BIT763 -2.358 35.735 
BIT764 11.555 6.438 
BIT765 19.546 20.575 
BIT766 -0.061 0.838 
BIT768 18.462 12.206 
BIT769 -42.468 20.734 
BIT770 -1.480 7.549 
BIT772 2.590 4.766 
BIT773 12.172 42.781 
BIT774 -0.039 0.284 
BIT776 26.702 10.972 
BIT777 0.148 1.563 
BIT778 26.127 10.833 
BIT779 21.155 13.862 
BIT780 38.078 68.580 
BIT781 48.083 27.568 
BIT782 18.952 17.923 
BIT784 -72.081 49.301 
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BIT785 -5.006 1.235 
BIT786 -10.032 5.492 
BIT789 65.163 32.843 
BIT790 7.956 4.077 
BIT791 11.459 24.915 
BIT793 -1.524 20.951 
BIT798 3.120 3.577 
BIT802 2.564 28.023 
BIT803 18.434 21.145 
BIT806 -46.640 22.007 
BIT810 -8.735 6.134 
BIT811 -32.373 32.742 
BIT812 -1.314 1.357 
BIT813 23.739 15.226 
BIT814 -0.186 2.223 
BIT816 -15.660 10.751 
BIT817 0.117 0.252 
BIT818 0.027 2.423 
BIT819 -1.894 7.676 
BIT820 30.050 22.759 
BIT821 4.651 10.902 
BIT822 1.634 2.454 
BIT823 68.774 29.005 
BIT824 -0.128 0.542 
BIT825 -30.926 13.436 
BIT826 -28.573 17.892 
BIT827 -0.060 0.248 
BIT828 -0.264 1.496 
BIT829 18.120 15.497 
BIT830 22.235 10.766 
BIT831 -0.227 9.525 
BIT833 0.981 0.557 
BIT834 11.568 11.027 
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BIT835 0.329 0.218 
BIT837 0.302 6.550 
BIT840 0.420 0.212 
BIT842 0.985 0.798 
BIT843 27.617 11.144 
BIT844 -0.519 0.244 
BIT846 -2.397 1.777 
BIT848 -0.845 1.119 
BIT849 -17.248 11.556 
BIT850 -5.299 3.072 
BIT854 -0.564 3.851 
BIT855 -164.664 103.873 
BIT859 2.252 7.385 
BIT861 -0.044 0.248 
BIT863 -0.080 0.404 
BIT865 -1.076 0.951 
BIT868 -7.943 66.815 
BIT870 -0.118 0.401 
BIT871 -4.227 5.965 
BIT872 11.542 14.107 
BIT874 -8.671 5.019 
BIT875 5.588 6.832 
BIT877 1.592 8.504 
BIT878 0.937 2.855 
BIT879 -0.234 1.115 
BIT880 -4.468 20.371 
BIT881 1.638 2.947 
BIT882 -8.589 8.570 
BIT883 -4.321 6.161 
BIT884 -2.518 13.847 
BIT886 -1.870 1.864 
BIT887 -0.318 0.395 
BIT888 -37.957 21.074 
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BIT889 1.281 1.070 
BIT890 22.628 18.008 
BIT891 -0.269 0.717 
BIT892 20.373 40.041 
BIT893 10.456 5.834 
BIT894 -19.582 13.416 
BIT896 -5.911 14.642 
BIT897 5.462 3.920 
BIT898 25.219 13.487 
BIT899 33.964 11.376 
BIT900 3.157 2.273 
BIT903 16.273 7.003 
BIT904 0.431 1.359 
BIT905 -1.784 3.262 
BIT906 7.462 8.141 
BIT907 -31.213 13.500 
BIT909 -5.004 8.424 
BIT910 -3.758 10.764 
BIT911 -0.363 0.328 
BIT912 7.622 14.453 
BIT913 0.854 0.286 
BIT914 -0.017 2.055 
BIT915 1.383 1.004 
BIT916 0.420 6.173 
BIT918 -17.003 6.700 
BIT919 0.648 1.682 
BIT920 0.338 0.539 
BIT921 4.698 4.857 
BIT922 -2.266 2.073 
BIT924 -0.608 0.292 
BIT925 -0.530 0.349 
BIT926 0.923 1.154 
BIT927 -12.029 12.135 
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BIT928 2.708 5.139 
BIT929 -0.053 0.717 
BIT930 -0.721 2.168 
BIT931 0.391 0.454 
BIT932 0.235 0.489 
BIT933 -0.280 1.653 
BIT934 1.635 0.805 
BIT935 2.391 3.171 
BIT936 9.353 10.611 
BIT937 7.660 4.463 
 
 
Table 4-2. The predicted values of logS by the built model using shape fingerprints. 
The table also includes values of experimental logS and predicted by MOE.98 
Molecule Experimental 
logS  
Predicted 
logS value 
Standard 
Error 
Predicted 
logS value by 
MOE 
1 -6.23 -5.85 0.13 -5.7 
2 -6.21 -5.09 0.16 -4.83 
3 -4.39 -3.9 0.32 -5.25 
4 -6.19 -6.29 0.46 -6.31 
5 -6.16 -6.81 0.17 -8.11 
6 -6.15 -6.64 0.48 -4.54 
7 -3.68 -6.82 0.46 -3.59 
8 -6.08 -4.17 0.21 -6.24 
9 -6.04 -3.9 0.32 -3.76 
10 -5.14 -5.76 0.18 -6.2 
11 -6.01 -6.11 0.15 -6.01 
12 -2.97 -4.31 0.26 -4.45 
13 -5.47 -3.73 0.27 -5.64 
14 -5.84 -5.13 0.19 -6.06 
15 -5.97 -7.24 0.56 -6.69 
16 -5.96 -7.48 0.57 -4.32 
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17 -5.93 -4.11 0.65 -5.8 
18 -5.79 -4.51 0.15 -4.26 
19 -5.85 -2.94 0.22 -3.79 
20 -5.91 -3.14 0.5 -5.28 
21 -5.38 -4.07 0.34 -5.38 
22 -5.87 -4.02 0.52 -6.87 
23 -5.88 -3.53 0.37 -4.25 
24 -5.84 -3.51 0.41 -5.84 
25 -5.83 -5.68 1.04 -6.57 
26 -5.82 -4.59 0.45 -7.51 
27 -5.8 -4.73 0.2 -4 
28 -5.8 -4.79 0.22 -5.35 
29 -5.1 -4.81 0.15 -5.11 
30 -5.74 -1.67 0.36 -3.75 
31 -5.72 -6.52 0.24 -7.86 
32 -5.71 -7.01 0.7 -6.25 
33 -5.69 -1.64 0.32 -5.95 
34 -5.67 -5.24 0.47 -6.3 
35 -4.48 -4.48 0.21 -5.43 
36 -5.65 -5.34 0.18 -4.83 
37 -5.63 -5.24 0.48 -5.5 
38 -5.62 -5.71 0.19 -5.16 
39 -5.55 -3.85 0.3 -2.77 
40 -5.52 -3.86 0.27 -5.31 
41 -5.51 -3.64 0.29 -5.96 
42 -5.5 -5.2 0.27 -7.11 
43 -5.44 -4.79 0.46 -5.89 
44 -5.44 -4.37 0.27 -5.16 
45 -5.43 -6.68 0.28 -7.3 
46 -5.42 -4.27 0.16 -5.97 
47 -5.4 -5.28 0.21 -5.58 
48 -5.4 -4.3 0.22 -4.64 
49 -5.32 -3.02 0.45 -5.05 
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50 -5.3 -5.11 0.51 -4.01 
51 -3.26 -4.26 0.27 -4.59 
52 -5.28 -3.5 0.25 -5.41 
53 -5.28 -2.53 0.11 -6.39 
54 -5.03 -4.18 0.17 -4.41 
55 -5.27 -4.15 0.22 -4 
56 -5.27 -4.98 0.37 -6.79 
57 -5.22 -3.9 0.27 -4.31 
58 -5.15 -5.11 0.59 -5.08 
59 -5.2 -1.98 0.25 -3.12 
60 -5.19 -4.51 0.28 -4.3 
61 -5.19 -4.11 0.31 -6.75 
62 -5.18 -6.5 0.34 -9.6 
63 -3.61 -2.63 0.26 -4.18 
64 -1.74 -4.02 0.41 -4.46 
65 -5.12 -3.12 0.22 -4.52 
66 -5.12 -1.63 0.81 -5.45 
67 -5.03 -2.54 0.36 -4.95 
68 -5.11 -3.92 0.19 -4.24 
69 -5.08 -3.44 0.19 -2.54 
70 -5.07 -3.8 0.22 -5.36 
71 -4.98 -6.58 0.24 -5.7 
72 -5.05 -4.23 0.23 -3.66 
73 -2.93 -3.98 0.27 -4.22 
74 -5.02 -3.46 0.22 -4.27 
75 -4.53 -2.71 0.32 -5.49 
76 -5.03 -2.83 0.27 -5.09 
77 -5.02 -3.78 0.46 -4.87 
78 -5.01 -3.85 0.29 -4.58 
79 -5.01 -4.39 0.11 -6.28 
80 -4.95 -5.72 0.2 -5.33 
81 -4.93 -4.11 0.46 -4.97 
82 -4.91 -3.56 0.19 -3.66 
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83 -4.9 -5.43 0.52 -4.02 
84 -4.9 -2.46 0.71 -3.8 
85 -4.9 -3.25 0.33 -4.02 
86 -2.08 -3.48 0.34 -4.87 
87 -4.86 -7.01 0.93 -5.07 
88 -4.86 -5.97 0.23 -5 
89 -4.85 -4.17 0.42 -4.68 
90 -4.85 -4.52 0.18 -4.99 
91 -3.25 -3.29 0.28 -3.51 
92 -4.83 -5.58 0.19 -4.97 
93 -4.37 -4.38 0.46 -4.8 
94 -4.8 -4.05 0.84 -3.94 
95 -4.79 -5.91 0.7 -4.29 
 
The predicted values do not vary much from those obtained from well-established logS 
prediction software. Many compounds have either a similar or slightly worse predicted 
logS values. However, for a few compounds the values are much closer to 
experimental logS values than the ones predicted by MOE. This was summarized in 
the form of a plot (Figure 4-6).  
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Figure 4-6. The plot of predicted logS values vs. experimental values for shape 
fingerprints and MOE. The 1:1 line is included.  
Some predicted solubility values differ from the experimental ones more than the 
others. The logS values are not accurately predicted for the structures of molecules 
shown in the Figure 4-7.  
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B) 
 
Figure 4-7. The structures of compounds that predicted solubility differs much from 
experimental: A) predicted logS = -6.82, while experimental logS = -3.68; B) 
predicted logS = -1.64 and experimental logS = -5.69. 
 
The second set containing all molecules with measured logS had 4194 compounds in 
the training set and 464 compounds in the test set. The model was built in a similar 
way as described above. The results are shown in the Figure 4-8 in comparison to 
experimental logS values. 
 
Figure 4-8. The plot of predicted logS values for 464 compounds vs. experimental 
values for shape fingerprints. The 1:1 line is included. 
In second set, some of the logS values were poorly predicted, they vary much from 
the experimental values. The examples of the structures of the molecules with such 
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poor prediction are show in the Figure 4-9. Most probable reason for some of the 
extreme results is that the interaction of molecule with water plays more important 
role than its shape. For others, when the actual solubility is worse than the predicted 
one, probably form strong intermolecular bonds in the crystal lattice. The consequence 
of that is the difficulty of predicting solubility using shape fingerprints method.  
A) 
 
C) 
 
B) 
 
D) 
 
Figure 4-9. The structures of compounds that predicted solubility differs much from 
experimental: A) predicted logS = 18.61, while experimental logS = -5.70; B) 
predicted logS = -26.38 and experimental logS = -5.05; C) predicted logS = -27.22 
and experimental logS = -5.74; D) predicted logS = -7.26 and experimental logS = 
1.04. 
 
The proposed model predicts the aqueous solubility without the use of any 
experimental data. The only necessary data points are the calculated logP and shape 
fingerprints. As it produces similar results to MOE, it could be used simultaneously 
with it to predict quite accurately the values of logS.  
4.4.1.2. The set of 100 compounds – all Shape Databases 
The shape fingerprints were calculated for each compound from the set of randomly 
chosen 100 molecules (all 100 molecules had both MP and logS values) using all of 
the Shape Databases and different settings: 1) DT = 0.50, BOV = 0.50, 2) DT = 0.50, 
BOV = 0.70, 3) DT = 0.70, BOV = 0.50 and 4) DT = 0.70, BOV = 0.70. The prediction 
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of solubility of the set of compounds was performed using SPSS,119. The independent 
values were selected to be calculated logP (computed in MOE)98 and all the bits from 
the generated shape fingerprint string. The applied method was ‘Enter’, which means 
that all independent variables are entered into the equation in one step. The results are 
shown in Table 4-3 as adjusted R2 for each Shape Database with each setting listed 
above. The model using clogP and MP to predict logS was applied as benchmark, 
where the obtained R2 was equal to 0.694. 
Table 4-3. The adjusted R2 values obtained from SPSS.119 
SHAPE 
DATABASE 
DT = 0.50; 
BOV = 0.50 
DT = 0.50; 
BOV = 0.70 
DT = 0.70; 
BOV = 0.50 
DT = 0.70; 
BOV = 0.70 
SD01 0.739 0.676 0.909 0.733 
SD02 0.729 0.642 0.915 0.754 
SD03 0.71 0.666 0.796 0.719 
SD04 0.708 0.641 0.755 0.706 
SD05 0.77 0.641 0.79 0.691 
SD06 0.766 0.656 0.628 0.747 
SD07 0.712 0.643 1 0.754 
SD08 0.708 0.647 0.647 0.74 
SD09 0.668 0.661 0.737 0.705 
SD10 0.746 0.641 0.642 0.78 
 
The highest values of R2 were obtained for SD07 with DT = 0.70 and BOV = 0.50, 
and only a little lower for SD01 and SD02 with the same settings. This suggests that 
using a high DT and slightly lower BOV gives the best results in building models for 
solubility prediction. However, the high scores (especially R2 =1) were probably the 
effect of overfitting, as the number of terms included in model in case was too high 
compared to the number of compounds used in prediction (100). It is also worth noting 
that there is no Shape Database that performs the best across all of the applied settings.  
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4.5. Nuclear Receptors 
Nuclear receptors (NRs) are a protein superfamily that bind and respond to certain 
steroid hormones, e.g. estrogen and progesterone, and a range of other signalling 
molecules, such as retinoic acid and thyroid hormone.120,121 The superfamily is 
classified as transcription factors due to their ability to directly bind DNA and control 
the expression of genomic DNA. The NRs play an important role in many 
physiological functions such as cell proliferation, development, metabolism, and 
reproduction.120,121 Many NRs also regulate a number of proteins involved in 
xenobiotic metabolism, which protects the organism against potentially toxic 
compounds (cytochrome P450 family).120,122  
Although, there are 48 known NRs encoded in the human genome,123 for some of them 
neither physiological function nor natural ligands are known. These are called orphan 
receptors.123 This includes e.g. estrogen-related receptor and human nuclear factor 4.  
The molecular structure of NRs is very similar. Almost all of the nuclear receptors 
have two structural domains: a DNA-binding domain (DBD) and C-terminal ligand-
binding domain (LBD).123,124 Members of this superfamily also contain an N-terminal 
transactivation domain.123 The DBD domain, which is the most conserved segment of 
NRs,124 contains two zinc ions coordinated by four cysteine residues.  
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Figure 4-10. The structures of some of the NRs ligands.125 
As already mentioned, among NR ligands (Figure 4-10) there are retinoic acids, 
steroids and thyroid hormones.126 They can be characterized as lipophilic, large (200-
1600 Da) molecules that need to cross the plasma membrane in order to bind to the 
hydrophobic pocket of its receptor. 121,125  
The image originally presented here cannot be made freely 
available via LJMU E-Theses Collection because of copyright 
restrictions. The image was sourced at 
Sladek, F. M. What Are Nuclear Receptor Ligands? Mol. Cell. 
Endocrinol. 2011, 334 (1–2), 3–13. 
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Figure 4-11. Nuclear receptor signaling.121 Abbreviations: HSP – Heat Shock Protein; 
ER – Estrogen receptor; RXR – Retinoid X Receptor; NR – Nuclear Receptor; ERE – 
Estrogen Response Element; TRE – Thyroid Hormone Response Element; LXRE – 
Liver X Response Element. 
When the natural small lipophilic ligands bind to their nuclear receptor, it activates the 
signalling pathway, as shown in the Figure 4-11, based on one of four modes of 
actions: 1) the ligand frees the receptor from the chaperone, which allows the created 
complex to enter into the nucleus, where the complex forms interactions with 
coactivators and the target genes are activated (e.g. the estrogen receptor, the 
progesterone receptor); 2) ligand by binding to the receptor causes dissociation of the 
corepressors that interact with it and their replacement with coactivators (e.g. thyroid 
hormone receptor, retinoid acid receptor); 3) similarly to type 1 but with different 
organization of the hormone response elements (HREs); 4) bind as monomers to a 
single half site HREs.121  
The image originally presented here cannot be made freely available via LJMU 
E-Theses Collection because of copyright restrictions. The image was sourced at 
Sever, R.; Glass, C. K. Signaling by Nuclear Receptors. Cold Spring Harb. 
Perspect. Biol. 2013, 5 (3). 
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4.5.1. Methods 
The database of various NRs ligands was obtained from C. Mellor and F. Steinmetz.127 
The list includes identified NR agonists expanded with data from the ChEMBL 
database of bioactive molecules.79 The set comprises of the 22 NRs: the aryl 
hydrocarbon receptor (AHR), two estrogen receptors (ER): ER-alpha, ER-beta, the 
glucocorticoid receptor (GR), the progesterone receptor (PR), vitamin D receptor 
(VDR), the thyroid hormone receptor (TR), three retinoic acid receptors (RAR): RAR-
alpha, RAR-beta, RAR-gamma, the pregnane X receptor (PXR), three types of 
peroxisome proliferator-activated receptors (PPAR): PPAR-alpha, PPAR-gamma, 
PPAR-delta, two isoforms of the liver X receptor (LXR): LXR-alpha, LXR-beta, 
farnesoid X receptor (FXR), two thyroid hormone receptors (THR): THR-alpha, THR-
beta and three retinoid X receptors (RXR): RXR-alpha, RXR-beta, RXR-gamma. The 
set was updated into a MySQL database,128 which stored all ligands with added 
information of all the receptors that it binds to. This enabled easy access to those 
ligands that interact with only specific NRs and not with others.  
The conformations were generated for every compound using Openeye’s OMEGA.83 
The number of maximum conformations was set to 5. The shape fingerprints were 
calculated with SD10 and settings DT = 0.65 and BOV = 0.60. Two summary values 
were used when comparing the conformations of ligands: 1) the highest value of FT 
amongst the array arising from comparisons of all conformations of one molecule with 
all conformations of the other was selected or 2) the average of those values was 
selected.  
Two approaches were applied. In the first, the shapes of all the ligands for each 
receptor were compared. This will show the NRs in which the shape of molecules 
plays a crucial role. In the second, a selected number of ligands from each receptor 
was compared to a set of structures including ones that bind to each of the NRs and 
decoys generated by DUD-E.90  
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4.5.2. Comparing the shape of ligands binding to each receptor 
The comparison of shapes of ligands binding to the same receptor was performed to 
examine how important shape is for some of the targets and to find those receptors for 
which the shape is not an important attribute of its ligands. 
Among all of the NRs, the strongest shape similarity between ligands is visible in the 
case of AHR (Figure 4-12), ER-alpha (Figure 4-13), ER-beta (Figure 4-14), PR 
(Figure 4-18), THR-alpha (Figure 4-26) THR-beta (Figure 4-27) and GR (Figure 
4-29). For those targets, the similarity between molecules is quite high for the whole 
set, especially when using the MV method. The AV method for those NRs shows 
slightly lower values of ST. In the case of TR (Figure 4-28), PXR (Figure 4-19), 
RAR-alpha (Figure 4-20), RAR-beta (Figure 4-21) RAR-gamma (Figure 4-22), 
RXR-alpha (Figure 4-23), RXR-beta (Figure 4-24), RXR-gamma (Figure 4-25) and 
VDR (Figure 4-30) it can be observed that there are a few groups of ligands which 
are similar in shape, but this similarity is not shared across the whole set of molecules. 
The lack of shape similarity can be noticed for FXR (Figure 4-15), LXR-alpha 
(Figure 4-16) and LXR-beta (Figure 4-17) independently of the comparison method 
used (AV and MV).  
  
Figure 4-12. Heatmap of STs for AHR ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by shape fingerprints method. 
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Figure 4-13. Heatmap of STs for ER-alpha ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
Figure 4-14. Heatmap of STs for ER-beta ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
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Figure 4-15. Heatmap of STs for FXR ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by the shape fingerprints method. 
Figure 4-16. Heatmap of STs for LXR-alpha ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
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Figure 4-17. Heatmap of STs for LXR-beta ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
Figure 4-18. Heatmap of STs for PR ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by the shape fingerprints method. 
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Figure 4-19. Heatmap of STs for PXR ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by the shape fingerprints method. 
Figure 4-20. Heatmap of STs for RAR-alpha ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
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Figure 4-21. Heatmap of STs for RAR-beta ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
  
Figure 4-22. Heatmap of STs for RAR-gamma ligands when using MV (on the left) 
and AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
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Figure 4-23. Heatmap of STs for RXR-alpha ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
 
Figure 4-24. Heatmap of STs for RXR-beta ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
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Figure 4-25. Heatmap of STs for RXR-gamma ligands when using MV (on the left) 
and AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
Figure 4-26. Heatmap of STs for THR-alpha ligands when using MV (on the left) and 
AV method (on the right). The darker the colour, the higher the shape similarity 
detected by the shape fingerprints method. 
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Figure 4-27. Heatmap of STs for THRb ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by the shape fingerprints method. 
Figure 4-28. Heatmap of STs for TR ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by the shape fingerprints method. 
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Figure 4-29. Heatmap of STs for GR ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by the shape fingerprints method. 
  
Figure 4-30. Heatmap of STs for VDR ligands when using MV (on the left) and AV 
method (on the right). The darker the colour, the higher the shape similarity detected 
by the shape fingerprints method. 
4.5.3. Virtual Screening of NRs 
In order to check the ability to distinguish the ligands binding to one receptor from 
those binding to the others, the set of 50 compounds from each set was taken and 
analysed together with a set of molecules binding to all the other receptors. 
Additionally, a set of decoys was added for better comparison.  
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Figure 4-31. The heatmap of comparison of AHR ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of AHR ligands. 
The shapes of AHR ligands (Figure 4-31) are very similar to each other and differ 
clearly from the ligands of the rest of the receptors. The similarity between compounds 
is maintained even when using the AV method to compare the conformations of the 
molecules, which shows that the generated conformations by OMEGA are quite 
similar to each other.  
  
Figure 4-32. The heatmaps of comparison of ER-alpha ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of ER-alpha ligands. 
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In the case of ER-alpha (Figure 4-32), the strong similarities between shapes of its 
ligands can be observed only when using the MV method, while the AV method does 
not show any differentiation between the ER-alpha ligands and the ligands of other 
receptors. It is worth noting that ligands that bind to the ER-beta also have a high 
Shape Tanimoto with most of the ER-alpha ligands, which is expected as both 
isoforms have similar binding pockets and therefore their ligands can share similar 
shape.  
  
Figure 4-33. The heatmaps of comparison of ER-beta ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of ER-beta ligands. 
The ER-beta ligands (Figure 4-33) do not share STs that are as high as with ER-alpha, 
when using the MV method. However, they show much higher similarity when taking 
the average value of Shape Tanimotos. This suggests that conformations of ER-beta 
ligands have similar shape and that there might be some more conformational variation 
tolerated in the ER-beta than in the ER-alpha.  
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Figure 4-34. The heatmaps of comparison of FXR ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of FXR ligands. 
The FXR ligands (Figure 4-34) clearly do not show much similarity in shape using 
either of the applied methods and cannot be distinguished from ligands of other 
receptors. This could be expected, as the previous study from this chapter showed 
really low similarities amongst the shape of FXR ligands. A similar situation can be 
observed in the case of other receptors: GR (Figure 4-35), LXR-alpha (Figure 4-36), 
LXR-beta (Figure 4-37), PPAR-alpha (Figure 4-38), PPAR-delta (Figure 4-39) and 
PPAR-gamma (Figure 4-40). The ligands do not have many commonalities in shape 
and are difficult to distinguish from ligands of other receptors.  
  
Figure 4-35. The heatmaps of comparison of GR ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
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darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of GR ligands. 
  
Figure 4-36. The heatmaps of comparison of LXR-alpha ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of LXR-alpha ligands. 
  
Figure 4-37. The heatmaps of comparison of LXR-beta ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of LXR-beta ligands. 
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Figure 4-38. The heatmaps of comparison of PPAR-alpha ligands with ligands of 
other receptors with decoys when using MV (on the left) and AV method (on the 
right). The darker the colour, the higher the shape similarity detected by shape 
fingerprints method. The box (top left) encloses the set that binds of PPAR-alpha 
ligands. 
  
Figure 4-39. The heatmaps of comparison of PPAR-delta ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of PPAR-delta ligands. 
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Figure 4-40. The heatmaps of comparison of PPAR-gamma ligands with ligands of 
other receptors with decoys when using MV (on the left) and AV method (on the 
right). The darker the colour, the higher the shape similarity detected by shape 
fingerprints method. The box (top left) encloses the set that binds of PPAR-gamma 
ligands. 
In the case of PR (Figure 4-41), PXR (Figure 4-42) RAR-alpha (Figure 4-43), RAR-
beta (Figure 4-44), RAR-gamma (Figure 4-45), RXR-alpha (Figure 4-46), RXR-beta 
(Figure 4-47) and RXR-gamma (Figure 4-48), there is some barely noticeable 
similarity between ligands however it is small and it is not easy to see the difference 
from other receptor ligands and decoys. 
  
Figure 4-41. The heatmaps of comparison of PR ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of PR ligands. 
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Figure 4-42. The heatmaps of comparison of PXR ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of PXR ligands. 
Figure 4-43. The heatmaps of comparison of RAR-alpha ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of RAR-alpha ligands. 
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Figure 4-44. The heatmaps of comparison of RAR-beta ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of RAR-beta ligands. 
Figure 4-45. The heatmaps of comparison of RAR-gamma ligands with ligands of 
other receptors with decoys when using MV (on the left) and AV method (on the 
right). The darker the colour, the higher the shape similarity detected by shape 
fingerprints method. The box (top left) encloses the set that binds of RAR-gamma 
ligands. 
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Figure 4-46. The heatmaps of comparison of RXR-alpha ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of RXR-alpha ligands. 
  
Figure 4-47. The heatmaps of comparison of RXR-beta ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of RXR-beta ligands. 
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Figure 4-48. The heatmaps of comparison of RXR-gamma ligands with ligands of 
other receptors with decoys when using MV (on the left) and AV method (on the 
right). The darker the colour, the higher the shape similarity detected by shape 
fingerprints method. The box (top left) encloses the set that binds of RXR-gamma 
ligands. 
The THR-alpha (Figure 4-49), THR-beta (Figure 4-50) and VDR (Figure 4-52) 
ligands clearly show high shape similarity and are easily distinguished by the shape 
fingerprints method from other ligands and decoys.  
Figure 4-49. The heatmaps of comparison of THR-alpha ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of THR-alpha ligands. 
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Figure 4-50. The heatmaps of comparison of THR-beta ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of THR-beta ligands. 
  
Figure 4-51. The heatmaps of comparison of TR ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of TR ligands. 
The VDR ligands are one of the easiest to distinguish from ligands of other receptors, 
but only when using the MV method of comparison. The calculated STs are high for 
VDR ligands and really small, close to 0-0.2 ST when compared with shapes of other 
ligands. In the case of the AV method this is not that easily noticeable. The values are 
much smaller, however so are the ST values for other ligands – almost all the 
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comparison between VDR ligands and other receptor ligands have values 0, which 
indicates complete dissimilarity.  
 
Figure 4-52. The heatmaps of comparison of VDR ligands with ligands of other 
receptors with decoys when using MV (on the left) and AV method (on the right). The 
darker the colour, the higher the shape similarity detected by shape fingerprints 
method. The box (top left) encloses the set that binds of VDR ligands. 
These sets of data have been analysed with ROC curves. As can be seen in the Table 
4-4, the highest AUC values are obtained for AHR, PR, TR. This indicates that the 
discrimination between ligands binding to these receptors and the set of other ligands 
and decoys, is the highest in these sets. The values are higher than the ones calculated 
for Test Sets 1 and 2 in chapter 2. Those were equal to 0.61 and 0.61 for Test Set 1 
when using AV and MV approaches, respectively and 0.77 and 0.78 for Test Set 2 
when using AV and MV methods, respectively. The AUC values results are 
complemented by logistic regression plots for each of the NRs. Some of the plots, like 
Figure 4-56, Figure 4-57, Figure 4-58, Figure 4-59, Figure 4-60, Figure 4-61 and 
Figure 4-62, clearly shows the poor discrimination between true positives (ligands) 
and true negatives (decoys). 
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Table 4-4. The comparison of AUC values for all NRs using both methods: AV and 
MV. 
NR AV MV 
AHR 0.83 0.81 
ER-ALPHA 0.63 0.72 
ER-BETA 0.63 0.64 
FXR 0.56 0.54 
GR 0.52 0.52 
LXR-ALPHA 0.52 0.50 
LXR-BETA 0.49 0.51 
PPAR-ALPHA 0.55 0.61 
PPAR-DELTA 0.59 0.53 
PPAR-GAMMA 0.60 0.57 
PR 0.76 0.74 
PXR 0.56 0.55 
RAR-ALPHA 0.65 0.67 
RAR-BETA 0.63 0.64 
RAR-GAMMA 0.67 0.69 
RXR-ALPHA 0.68 0.70 
RXR-BETA 0.65 0.67 
RXR-GAMMA 0.63 0.65 
THR-ALPHA 0.66 0.69 
THR-BETA 0.68 0.71 
TR 0.78 0.77 
VDR 0.63 0.70 
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Figure 4-53. The logistic regression plots of comparison of AHR ligands with ligands 
of other receptors with decoys when using MV (on the left) and AV method (on the 
right). 
 
Figure 4-54. The logistic regression plots of comparison of ER-alpha ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
134 | P a g e  
 
Figure 4-55. The logistic regression plots of comparison of ER-beta ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
Figure 4-56. The logistic regression plots of comparison of FXR ligands with ligands 
of other receptors with decoys when using MV (on the left) and AV method (on the 
right). 
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Figure 4-57. The logistic regression plots of comparison of GR ligands with ligands 
of other receptors with decoys when using MV (on the left) and AV method (on the 
right). 
 
Figure 4-58. The logistic regression plots of comparison of LXR-alpha ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
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Figure 4-59. The logistic regression plots of comparison of LXR-beta ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
Figure 4-60. The logistic regression plots of comparison of PPAR-alpha ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
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Figure 4-61. The logistic regression plots of comparison of PPAR-delta ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
Figure 4-62. The logistic regression plots of comparison of PPAR-gamma ligands 
with ligands of other receptors with decoys when using MV (on the left) and AV 
method (on the right). 
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Figure 4-63. The logistic regression plots of comparison of PR ligands with ligands 
of other receptors with decoys when using MV (on the left) and AV method (on the 
right). 
 
Figure 4-64. The logistic regression plots of comparison of PXR ligands with ligands 
of other receptors with decoys when using MV (on the left) and AV method (on the 
right). 
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Figure 4-65. The logistic regression plots of comparison of RAR-alpha ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
  
Figure 4-66. The logistic regression plots of comparison of RAR-beta ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
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Figure 4-67. The logistic regression plots of comparison of RAR-gamma ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
Figure 4-68. The logistic regression plots of comparison of RXR-alpha ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
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Figure 4-69. The logistic regression plots of comparison of RXR-beta ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
Figure 4-70. The logistic regression plots of comparison of RXR-gamma ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
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Figure 4-71. The logistic regression plots of comparison of THR-alpha ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
 
Figure 4-72. The logistic regression plots of comparison of THR-beta ligands with 
ligands of other receptors with decoys when using MV (on the left) and AV method 
(on the right). 
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Figure 4-73. The logistic regression plots of comparison of TR ligands with ligands 
of other receptors with decoys when using MV (on the left) and AV method (on the 
right). 
Figure 4-74. The logistic regression plots of comparison of VDR ligands with ligands 
of other receptors with decoys when using MV (on the left) and AV method (on the 
right). 
4.6. Conclusions 
As presented in this chapter, the shape fingerprints method can be successfully applied 
to solve many problems in the chemistry world. This includes predictions of solubility 
similarly to well-established approaches, virtual screening and shape similarity 
searches.  
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The results presented in this chapter showed that the shape fingerprint method could 
be successfully applied not only to small sets, like Test Set 1 and Test Set 2 from 
chapter 2, but also to much larger sets such as DUD-E diverse set (consisting of 8 
targets with 1774 ligands in total). Grouping compounds from DUD-E diverse set 
based on the similar biological activity performed a little worse than in case of smaller 
sets. However, the obtained AUC value of 0.55 could have been expected as the size 
of the presented set is much greater than used previously.  
The AUC values obtained from virtual screening on three sets taken from DUD-E 
(AMPC, COMT and CXCR4), consisting of ligands and a series of decoys, reveal the 
potential of shape fingerprints application as a ligand-based virtual screening 
technique. The results: 0.57, 0.66 and 0.62 for CXCR4, AMPC and COMT sets 
respectively are decent considering the size of the sets and the high ratio of decoys per 
ligand in each set.  
Another potential application of shape fingerprints shown in this chapter is the 
solubility prediction. The predicted logS values are comparable (and in some case the 
predicted values are much closer to experimental ones) to those obtained using well-
established prediction software. As it produces similar results to MOE, it could be 
used simultaneously with it to predict quite accurately the values of logS. The 
approach could be improved by including also the chemistry of compounds (using 
Tanimoto Combo score instead of Shape Tanimoto in generating Shape Database and 
shape fingerprints). This might reduce number of poorly predicted solubility values 
for molecules that solubility measurements could be affected by too strong interaction 
of molecules with solute or too strong intermolecular interactions in crystal lattice and 
therefore are difficult to predict with shape-only techniques.  
Applying shape fingerprint method to 22 sets of NRs ligands showed in which NRs 
the shape plays crucial role. Among all of the NRs, the strongest shape similarity 
between ligands is visible in the case of AHR, ER-alpha, ER-beta PR, THR-alpha, 
THR-beta. Therefore, these sets performed well also in virtual screening of NRs – they 
had high AUC values and were easily distinguished from ligands of other NRs and 
decoys. In the case of TR, PXR, RAR-alpha, RAR-beta, RAR-gamma, RXR-alpha, 
RXR-beta, RXR-gamma and VDR it can be observed that there are a few groups of 
ligands which are similar in shape, but this similarity is not shared across the whole 
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set of molecules. The lack of shape similarity can be noticed for FXR, LXR-alpha and 
LXR-beta. 
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Chapter 5  
 
 
Matched Molecular Pairs 
 
 
 
 
 
5.1. Introduction 
Matched Molecular Pairs Analysis (MMPA) is a widely used approach to screen large 
databases in order to find pairs of molecules with a common structural part but 
differing by a small, well-defined change in structure and with a known change in 
properties.52,51,49,50 This approach assumes that the change of properties is more easily 
predicted than the absolute values of those properties for each molecule alone. A 
matched molecular pair (MMP) involves two compounds that have a common core 
and have a different fragment R as show in the Figure 5-1.  
  
Figure 5-1. An example of pair of MMPs with the changing fragment part marked in 
red circle. 
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There are two common approaches used to find MMPs: Fragment and Index (F+I)53 
and Maximum Common Substructure (MCSS).54 The comparison of how both 
methods find the MMPs can be found in the Figure 5-2.  
 MOLECULE A MOLECULE B 
 
  
 Fixed Part Changing Part Fixed Part Changing 
Part 
MCSS 
   
F+I 
   
Figure 5-2. The MMP, Molecule A and B, identified by two methods: Fragment and 
Index (F+I) and Maximum Common Substructure (MCSS) with shown fixed and 
changing parts. 
In the MCSS approach, as used in the WizePairZ algorithm described by Warner et 
al.,54 two molecules are compared and the maximum common substructure shared by 
them is identified – it is called the fixed part or the core. The remaining part is called 
the changing part as can be seen in the example in Figure 5-2, where the structural 
change is the change from C-Cl to N. In order to compare the molecules using this 
approach, the molecules are converted into graphs, which enables identifying common 
substructures between compounds. The structural change identified by the MCSS 
approach is encoded as SMIRKS, which is a reaction transform languagge.55  
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The disadvantages of the MCSS approach are that the substructure comparison is slow 
and that most algorithms for finding the MCSS require all of the atoms to be 
contiguous and therefore prevent pairs in which linkers change from being found.   
A second approach was introduced by Hussain and Rea.53 The algorithm works by 
generating fragments of the molecule based on predefined rules and then indexing 
those fragments, as shown in the example in Figure 5-2, where the structural change 
is from Clc1ccccc1 to c1ccnc1. The generated fragments are stored as key – value 
pairs.53,56  
In the first step, each molecule is fragmented, by breaking a selected single bond (or 
bonds). Hussain and Rea53 used a SMARTS pattern to define the bonds that could be 
broken and these are limited to acyclic single bonds. The resulting fragments are stored 
as SMILES strings, which can be manipulated as text. This is a great advantage of the 
approach: after initial fragmentation, all subsequent steps toward the identification of 
matched pairs involve only rapid text processing. Another advantage comes from the 
fact that once a molecule has been fragmented, it can be added to the database, which 
is then available for comparison to any new molecule or to find new MMPs.  
Among the limitations of the fragment and index approach to finding matched pairs 
are that small changes to rings cannot be identified as pairs, highly substituted core 
changes are limited by the number of fragmentations considered, and the diversity of 
the structural changes can be limited by the restrictions that are imposed (usually 
heavy atom counts or ratio). One specific set of changes that are not readily identified 
is modifications to macrocyclic rings.  
5.2. Methods 
In order to find matched molecular pairs, the software developed by MedChemica – 
MCPairs129 was used. It has implemented two approaches of finding MMPs: the F+I 
method described by Hussain and Rea53 and the MCSS  algorithm described by 
Warner et al.54 The structural change linking pairs of molecules is encoded by 
SMIRKS, and these are modiﬁed to include differing levels of chemical context. The 
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chemical context is encoded using SMILES for the atoms in the fixed part that are 
connected to the changing part. There are four context levels, as shown in Figure 5-3. 
 
Figure 5-3. Definition of the chemical context for a matched molecular pair. 
Both methods need the heavy atom fractions to be set to limit the possible matches. 
The FI ratio is defined as the number of heavy atoms in the fixed part divided by the 
count in the changing part. In the case of the MCSS method, the ratio is the count of 
overlapping heavy atoms to the count of heavy atoms in the smaller molecule. These 
will be described as fF+I and fMCSS for F+I method and MCSS method, respectively. 
The outcome of changing these settings for both methods and the optimum settings 
will be described in section 5.3 and was part of the investigation from the paper 
included in the appendix.50 
5.3. Results 
Three sets of data extracted from the ChEMBL database88 were used to perform 
MMPA: inhibitors of the Epidermal Growth Factor Receptor (EGFR), ligands of the 
dopamine D1 receptor, and voltage-gated calcium channel subunit alpha Cav3.2. 
These three were selected from the ChEMBL database88 based on having measured 
IC50, Ki and EC50 data for EGFR, D1, and Cav 3.2, respectively. These comprised 
1010, 903, and 792 individual compounds, respectively. 
The very first run of both methods for EGFR with default settings was performed to 
check the difference in computational time needed to find pairs. It took 6 minutes and 
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16 seconds for the F+I method and 1 day 18 hours, 36 minutes and 27 seconds for the 
MCSS method. These results show how fast the F+I method is compared to MCSS, 
where longer times come from calculating the overlap between the molecules. This 
might be especially problematic when screening large datasets. 
Both methods (MCSS and F+I) have been applied to the sets described above. The 
exact number of pairs found by each method (and for each set) can be seen in Table 
5-1 and also in Figure 5-4. It can be noticed that the higher the fF+I, the greater the 
number of found pairs, which was expected. It is the opposite in the case of the MCSS 
method, as shown in Table 5-2 and in the Figure 5-5, where a lower fMCSS leads to a 
higher number of matched pairs. It comes from the differences in defining ratios fF+I 
and fMCSS, as explained in section 5.2. 
Table 5-1. Number of matched pairs found by the F+I method for all sets of 
compounds: EGFR, D1 and Cav 3.2. 
FFI EGFR D1 CAV 3.2 
0.1 358 1856 330 
0.2 978 4738 874 
0.3 2140 11982 2090 
0.4 4078 16324 4472 
0.5 7964 24312 8174 
0.6 15450 35644 16758 
0.7 31710 56096 35304 
0.8 157500 120678 175328 
0.9 381077 236594 298666 
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Table 5-2. Number of matched pairs found by the MCSS method for all sets of 
compounds: EGFR, D1 and Cav 3.2. 
FMCSS EGFR D1 CAV 3.2 
0.1 150538 123568 136218 
0.2 129752 122867 134039 
0.3 78795 86154 47743 
0.4 25426 50019 9074 
0.5 7564 31528 2584 
0.6 3727 24480 1370 
0.7 1994 17895 924 
0.8 1106 9678 718 
0.9 650 4550 503 
 
A high ratio fF+I means that pairs of molecules might be matched by very small 
fragments, like O, CH2 or CH3, which leads to a high number of found pairs using this 
method. Similarly, low fMCSS can lead to finding pairs with a really small number of 
overlapped atoms, which obviously results in a higher number of found pairs. It is also 
possible that setting fMCSS too high might lead to cases where almost all of the heavy 
atoms of one molecule are within the second molecule and this way the structural 
change could be only hydrogen or one or two heavy atoms. That could result in too 
low a number of found pairs being found by the MCSS method. Therefore, it is crucial 
to set the optimum fF+I and fMCSS. 
152 | P a g e  
 
 
Figure 5-4. Numbers of molecular pairs found by the F+I method for different settings 
of fF+I. 
 
 
Figure 5-5. Numbers of molecular pairs found by the MCSS method for different 
settings of fMCSS.  
It is also important to analyse the number of pairs found by both approaches and those 
that were matched using only one of the methods. This analysis can be performed in 
two ways. One is to simply count the number of pairs found by both methods. A 
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second is to reduce that number to include only those pairs that are matched in the 
exact same manner, which means they have the exact same transformation encoded as 
SMIRKS. The results can be seen in tables: Table 5-3, Table 5-4 and Table 5-5 for 
all three sets of compounds. Those are the percentages of pairs found by both 
approaches. Using high values of fF+I and low values of fMCSS gives the biggest number 
of pairs found in common. However, it can be seen in  Table 5-3 that using 0.4 and 
0.7 ff+I and fMCSS respectively gives over 40% pairs in common (of total number of 
pairs found by both methods separately). Similarly, in Table 5-4 and Table 5-5, it can 
be seen that using fF+I = 0.4 and fMCSS = 0.7 allows the most pairs in common to be 
found: 33.24% and 55.06% for D1 and Cav 3.2 set, respectively.   
When considering the number of the exact same transformations used by both 
methods, the overlap is smaller than when considering pairs of molecules, which 
means that a majority of them were paired for different reasons: the F+I method can 
ﬁnd changes of large groups (such as substituted phenyl rings) whereas the MCSS 
method localizes the structural change to the smallest part of the structure that is 
different between the two molecules in the pair. 
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Table 5-3. The percentage of matched pairs of molecules found in the EGFR set by 
both methods using the pair count. In brackets: the percentage of common pairs found 
by using the exact same transformations. 
  FI 
  0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 
MCSS 
0.9 
0.79 
(0.10) 
1.98 
(0.24) 
5.84 
(1.18) 
13.49 
(2.37) 
21.87 
(4.42) 
29.88 
(7.89) 
35.09 
(12.87) 
43.54 
(21.07) 
37.64 
(23.21) 
0.8 
1.31 
(0.15) 
3.31 
(0.37) 
9.71 
(1.79) 
20.82 
(3.53) 
30.41 
(6.45) 
38.26 
(10.98) 
39.97 
(15.93) 
38.93 
(20.01) 
23.39 
(15.98) 
0.7 
2.04 
(0.23) 
4.96 
(0.55) 
14.12 
(2.61) 
26.72 
(5.04) 
36.69 
(8.67) 
40.48 
(13.09) 
32.17 
(14.01) 
23.26 
(14.03) 
14.07 
(9.95) 
0.6 
2.97 
(0.31) 
6.92 
(0.74) 
17.89 
(3.37) 
27.73 
(6.18) 
32.90 
(9.76) 
28.36 
(11.49) 
19.03 
(9.87) 
13.06 
(8.86) 
7.69 
(5.73) 
0.5 
4.64 
(0.47) 
9.84 
(1.11) 
21.62 
(4.57) 
25.25 
(7.44) 
20.98 
(8.20) 
15.23 
(7.70) 
9.79 
(5.97) 
6.51 
(4.88) 
3.80 
(2.95) 
0.4 
7.77 
(0.80) 
11.98 
(1.75) 
15.88 
(5.22) 
11.36 
(5.35) 
6.96 
(3.82) 
4.86 
(3.04) 
3.04 
(2.10) 
1.96 
(1.58) 
1.14 
(0.91) 
0.3 
11.07 
(1.57) 
12.03 
(2.91) 
7.92 
(3.39) 
3.99 
(2.32) 
2.37 
(1.47) 
1.61 
(1.08) 
0.99 
(0.72) 
0.64 
(0.52) 
0.37 
(0.30) 
0.2 
12.14 
(2.11) 
10.40 
(2.98) 
5.13 
(2.32) 
2.57 
(1.51) 
1.47 
(0.93) 
0.99 
(0.67) 
0.61 
(0.44) 
0.39 
(0.32) 
0.23 
(0.18) 
0.1 
12.76 
(2.35) 
9.23 
(2.77) 
4.44 
(2.05) 
2.22 
(1.32) 
1.26 
(0.80) 
0.85 
(0.58) 
0.52 
(0.38) 
0.34 
(0.28) 
0.20 
(0.16) 
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Table 5-4. The percentage of matched pairs of molecules found in the D1 set by both 
methods using the pair count. In brackets: the percentage of common pairs found by 
using the exact same transformations. 
 
 
 FI 
  0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 
MCSS 
0.9 
5.44 
(0.71) 
7.91 
(1.37) 
15.66 
(2.83) 
20.20 
(4.27) 
23.24 
(5.95) 
27.36 
(8.23) 
29.27 
(10.33) 
26.48 
(15.54) 
24.26 
(16.66) 
0.8 
9.01 
(1.23) 
12.12 
(2.33) 
22.40 
(4.62) 
27.53 
(6.70) 
30.92 
(8.93) 
35.02 
(11.68) 
32.69 
(13.82) 
21.50 
(14.13) 
11.64 
(9.25) 
0.7 
11.75 
(1.91) 
15.30 
(3.51) 
24.65 
(6.58) 
28.64 
(9.09) 
31.11 
(11.52) 
33.24 
(14.07) 
29.16 
(14.64) 
12.11 
(9.00) 
6.49 
(5.40) 
0.6 
12.73 
(2.17) 
16.00 
(3.90) 
23.00 
(6.97) 
25.86 
(9.34) 
27.28 
(11.43) 
27.25 
(12.39) 
22.08 
(12.00) 
9.12 
(6.97) 
4.93 
(4.05) 
0.5 
14.49 
(2.61) 
17.65 
(4.60) 
23.92 
(7.93) 
26.13 
(10.33) 
25.61 
(11.23) 
21.77 
(10.57) 
17.60 
(10.05) 
7.32 
(5.62) 
3.98 
(3.20) 
0.4 
13.39 
(2.61) 
15.12 
(4.37) 
17.62 
(6.91) 
17.83 
(8.38) 
16.59 
(8.43) 
14.02 
(7.62) 
11.28 
(7.05) 
4.64 
(3.72) 
2.51 
(2.06) 
0.3 
11.57 
(2.65) 
11.96 
(4.12) 
11.60 
(5.44) 
10.68 
(5.90) 
9.83 
(5.68) 
8.26 
(4.93) 
6.62 
(4.46) 
2.70 
(2.24) 
1.46 
(1.21) 
0.2 
10.2 
(2.69) 
9.86 
(3.86) 
8.36 
(4.33) 
7.59 
(4.53) 
6.95 
(4.26) 
5.83 
(3.63) 
4.66 
(3.24) 
1.89 
(1.60) 
1.02 
(0.86) 
0.1 
10.24 
(2.71) 
9.83 
(3.84) 
8.32 
(4.31) 
7.55 
(4.51) 
6.92 
(4.24) 
5.80 
(3.61) 
4.64 
(3.23) 
1.88 
(1.59) 
1.02 
(0.85) 
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Table 5-5. The percentage of matched pairs of molecules found in the Cav 3.2 set by 
both methods using the pair count. In brackets: the percentage of common pairs found 
by using the exact same transformations. 
  FI 
  0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 
MCSS 
0.9 
0.46 
(0.10) 
0.73 
(0.16) 
4.02 
(0.80) 
9.68 
(1.67) 
22.59 
(3.32) 
35.26 
(5.79) 
48.24 
(10.57) 
53.70 
(19.61) 
50.89 
(28.81) 
0.8 
0.66 
(0.12) 
1.04 
(0.20) 
5.74 
(0.97) 
13.78 
(2.00) 
32.16 
(3.94) 
49.15 
(6.74) 
47.06 
(11.75) 
40.97 
(17.59) 
35.73 
(22.90) 
0.7 
0.84 
(0.15) 
1.34 
(0.25) 
7.36 
(1.23) 
17.58 
(2.53) 
38.51 
(4.91) 
55.06 
(7.69) 
48.76 
(11.61) 
33.40 
(15.57) 
27.80 
(19.14) 
0.6 
1.23 
(0.22) 
1.95 
(0.38) 
10.14 
(1.81) 
22.56 
(3.61) 
46.19 
(6.74) 
54.16 
(9.09) 
36.36 
(10.12) 
23.34 
(12.48) 
18.78 
(14.12) 
0.5 
2.08 
(0.37) 
3.26 
(0.63) 
15.20 
(2.94) 
29.20 
(5.44) 
41.05 
(9.34) 
33.07 
(7.53) 
20.72 
(7.49) 
12.78 
(8.10) 
10.05 
(8.24) 
0.4 
4.96 
(0.87) 
7.08 
(1.41) 
21.8 
(5.88) 
23.61 
(8.68) 
15.26 
(8.74) 
10.77 
(3.92) 
6.29 
(3.14) 
3.74 
(2.81) 
2.86 
(2.55) 
0.3 
11.64 
(2.31) 
12.85 
(3.15) 
12.62 
(8.47) 
6.19 
(5.83) 
3.30 
(2.70) 
2.14 
(1.02) 
1.22 
(0.70) 
0.71 
(0.58) 
0.54 
(0.50) 
0.2 
18.45 
(5.06) 
16.35 
(5.38) 
5.86 
(9.83) 
2.71 
(2.49) 
1.22 
(1.06) 
0.77 
(0.38) 
0.44 
(0.26) 
0.25 
(0.21) 
0.19 
(0.18) 
0.1 
18.75 
(5.16) 
16.24 
(5.34) 
5.82 
(9.70) 
2.67 
(2.46) 
1.20 
(1.04) 
0.76 
(0.38) 
0.43 
(0.25) 
0.25 
(0.20) 
0.19 
(0.18) 
 
There are a lot of pairs found only by one method and not the other. Some examples 
are shown in Figure 5-6, Figure 5-7 and Figure 5-8 for EGFR, D1 and Cav 3.2 sets. 
There are pairs found only by one of the method when using fMCSS = 0.7 for MCSS 
approach and fF+I = 0.4 for F+I approach. 
 Molecule A Molecule B 
F+I 
only 
 
 
 Nfixed  = 18; Nchanging = 6 Nfixed  = 18; Nchanging = 4 
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Molecule C 
 
Molecule D 
MCSS 
only 
 
N
N
N
 
 Nfixed  = 11; Nchanging = 2 Nfixed  = 11; Nchanging = 1 
Figure 5-6. Pairs found only by the MCSS (bottom) and F+I (top) methods when using 
the EGFR set. 
In Figure 5-6,  the pair found by only the F+I approach has a change from aromatic 
ring c1ccccc1 to acyclic chain C=CC#C (double cut is considered here). The number 
of heavy atoms in the changing part Nchanging is 6 for the molecule A and 4 for molecule 
B. The number of heavy atoms in the whole molecule Nmolecule is 24 and 22 for 
molecule A and B, respectively. Thus, the ratio Nchanging/Nmolecule is 0.25 for the first 
molecule and 0.18 for the second. These are below the specified fF+I = 0.4, so the pair 
is allowed. The fixed and changing part identified by MCSS in this case would be 
different. The Nfixed would be 14 and the ratio Nfixed/Nmolecule would be 0.58 and 0.63 
for molecule A and B, respectively. This is below the fMCSS cutoff and therefore the 
pair would not be allowed. 
The pair of compounds found only by the MCSS method have a change in the 
heteroaromatic ring, as shown in Figure 5-6. Such structural change in the aromatic 
ring would be not possible to find by using the F+I method as it requires breaking the 
bond to the aromatic ring which gives a changing part that is a large fraction of the 
molecule. For the first molecule the Nfixed, the number of heavy atoms in the fixed part, 
is 11 and Nmolecule is 13 and for the second molecule Nmolecule is 12. Therefore, the ratio, 
Nfixed/Nmolecule is 0.85 for the first molecule and 0.92 for the second. This is greater 
than the cutoff fMCSS used in this example (0.7), which is allowed. The pair would not 
be allowed in the F+I method as the ratio Nfixed/Nmolecule would be 0.54 and 0.5 for 
molecule C and D, respectively, which is greater than the fF+I cutoff (0.4). 
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 Molecule A Molecule B 
F+I 
only 
 
 
 Nfixed  = 14; Nchanging = 7 Nfixed  = 14; Nchanging = 5 
 Molecule C Molecule D 
MCSS 
only 
 
 
 Nfixed  = 20; Nchanging = 4 Nfixed  = 20; Nchanging = 4 
Figure 5-7. Pairs found only by the MCSS (bottom) and F+I (top) methods when using 
the D1 set. 
In Figure 5-7 the pair of compounds found only by the F+I method has the structural 
change from c1ccccc1I to CCCCC and the pair found by only the MCSS approach has 
the structural change includes part of aromatic ring and because of that was not 
possible to be found by the F+I method. In case of pair found only by the MCSS 
method, the ratio Nfixed/Nmolecule is 0.83 for both molecules, which is greater than the 
defined cutoff value (0.7) so the pair is allowed. Using the F+I method, the fragments 
would be identified differently and the ratio of Nchanging/Nmolecule would be 17/24 = 0.71 
for both molecules, which is greater than cutoff 0.4 and therefore would not be 
considered as a pair. 
In the case of the pair found only by the F+I method, the ratio Nchanging/Nmolecule is 0.33 
and 0.26 for molecules A and B respectively, which is below the used fF+I (0.4) and 
therefore the pair is allowed. When the MCSS approach is applied, the ratio 
Nfixed/Nmolecule is 0.67 and 0.74. As one of the molecule has a ratio lower than the cutoff 
value (0.7) therefore the pair is not allowed. 
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 Molecule A Molecule B 
F+I 
only   
 Nfixed  = 20; Nchanging = 6 Nfixed  = 20; Nchanging = 11 
 Molecule C Molecule D 
MCSS 
only 
 
 
 Nfixed  = 25; Nchanging = 3 Nfixed  = 25; Nchanging = 3 
Figure 5-8. Pairs found only by the MCSS (bottom) and F+I (top) methods when using 
the Cav3.2 set. 
In  Figure 5-8 the pair found by only the MCSS method has a change from CCC to 
CC(C). The pair has the Nfixed/Nmolecule equal to 0.89 and 0.89 for molecule A and B, 
respectively. As the ratios for the both molecules of the pair are above the specified 
fMCSS of 0.7, this pair is allowed. The F+I approach would not identify the pair as the 
obtained ratio would be greater than the fF+I cutoff (in this approach the ratio 
Nchanging/Nmolecule is 12/28 = 0.43 for both molecules) and therefore is not allowed.  
In the case of the pair found by the F+I approach, the molecule A has 0.23 and 
molecule B has 0.35 values for the ratio Nchanging/Nmolecule. This is below the fF+I  = 0.4, 
thus it is allowed. When using the MCSS approach, this pair would not be allowed as 
the ratio Nfixed/Nmolecule is 0.38 and 0.32 for molecule A and B, respectively. This is 
lower than the specified cutoff (0.7) and thus is not allowed. 
All the examples show that using both methods for MMPA simultaneously would be 
more advantageous, as none of the presented examples of found pairs is chemically 
unreasonable. This would significantly increase the chances of finding pairs worth 
considering.  
160 | P a g e  
 
5.4. Conclusions 
The analyses described in this chapter lead to that conclusion that in order to most 
thoroughly explore the effect of structural transformations on chemical properties, it 
might be reasonable to use both approaches, F+I and MCSS, simultaneously. This way 
it is possible to find MMPs that would be found by one method and not the other, like 
finding changes of linkers (which is the limitation of MCSS approach but can be found 
by using F+I method) or small changes in rings or highly substituted core changes that 
are among the limitations of F+I method but could be found easily using MCSS 
method.  
The choice of optimum settings for both methods is an important decision. A high 
ratio fF+I allows to find more pairs, but too high fF+I could lead to pairs that might be 
matched by very small fragments like O, CH2 or CH3. Similarly, setting too low fMCSS 
can lead to finding pairs with a really small number of overlapped atoms. On the other 
hand, too high fMCSS could result in matched pairs with almost all of the heavy atoms 
of one molecule are within the second molecule and this way the structural change 
could be only hydrogen or one or two heavy atoms.  
It could also be suggested that the optimum settings should see fF+I and the fMCSS set 
to 0.4 and 0.7, respectively. Such choice allows to good coverage of chemical space 
and find high number of matched pairs. As was shown in this chapter, choosing the 
aforementioned settings gives over ca. 33%, 40% and 55% pairs in common for 
EGFR, D1 and Cav3.2 set, respectively. Even though the majority of them were paired 
by each approach for different reasons: the F+I method can ﬁnd changes of large 
groups (such as substituted phenyl rings) whereas the MCSS method localizes the 
structural change to the smallest part of the structure that is different between the two 
molecules in the pair. 
Further analysis was conducted by the colleagues in the research  group50  and  lead to 
slightly  different conclusions - the optimum settings are fF+I=0.4 and  fMCSS=0.9.  The 
paper with full analysis and results was included in the appendix.  
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